Document and Entity Information	12 Months Ended
Document and Entity Information	Mar. 31, 2015
Document and Entity Information
Document Type	20-F
Amendment Flag	false
Document Period End Date	Mar. 31, 2015
Entity Registrant Name	China Cord Blood Corp
Entity Central Index Key	0001467808
Trading Symbol	CO
Current Fiscal Year End Date	--03-31
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	FY
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding	80,083,248
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes

Consolidated Balance Sheets In Thousands, unless otherwise specified	Mar. 31, 2015 USD ($)	Mar. 31, 2015 CNY	Mar. 31, 2014 CNY
Current assets
Cash and cash equivalents	$ 393,072	2,436,655	1,882,901
Trading securities	1,243	7,708
Accounts receivable, less allowance for doubtful accounts (March 31, 2014: RMB20,322; March 31, 2015: RMB28,624 (US$4,618))	19,480	120,762	95,273
Inventories	3,840	23,803	31,583
Prepaid expenses and other receivables	3,147	19,508	37,010
Debt issuance costs	579	3,592	3,616
Deferred tax assets	1,657	10,270	7,664
Total current assets	423,018	2,622,298	2,058,047
Property, plant and equipment, net	97,301	603,167	626,632
Non-current deposits	33,434	207,258	208,894
Non-current accounts receivable, less allowance for doubtful accounts (March 31, 2014: RMB42,703; March 31, 2015: RMB55,211 (US$8,906))	31,334	194,238	225,496
Inventories	9,392	58,224	48,385
Intangible assets, net	18,701	115,928	120,549
Available-for-sale equity securities	19,748	122,416	144,247
Other investment	30,510	189,129	189,129
Debt issuance costs	679	4,210	7,854
Deferred tax assets	422	2,618	1,789
Total assets	664,539	4,119,486	3,631,022
Current liabilities
Bank loan	9,679	60,000	60,000
Accounts payable	2,044	12,673	10,422
Accrued expenses and other payables	14,097	87,381	102,559
Deferred revenue	35,512	220,140	196,432
Amounts due to related parties	3,355	20,802	21,453
Income tax payable	1,626	10,081	2,571
Deferred tax liabilities	1,468	9,100	3,900
Total current liabilities	67,781	420,177	397,337
Convertible notes	131,610	815,851	777,753
Non-current deferred revenue	177,351	1,099,399	823,921
Other non-current liabilities	34,777	215,585	164,077
Deferred tax liabilities	4,075	25,261	27,938
Total liabilities	415,594	2,576,273	2,191,026
Shareholders' equity of China Cord Blood Corporation
Ordinary shares - US$0.0001 par value, 250,000,000 shares authorized, 73,140,147 shares issued and 73,003,248 shares outstanding as of March 31, 2014 and 2015, respectively	8	50	50
Additional paid-in capital	131,420	814,678	798,221
Treasury stock, at cost (March 31, 2014 and 2015: 136,899 shares, respectively)	(454)	(2,815)	(2,815)
Accumulated other comprehensive income	10,200	63,230	84,263
Retained earnings	106,891	662,615	555,323
Total equity attributable to China Cord Blood Corporation	248,065	1,537,758	1,435,042
Non-controlling interests	880	5,455	4,954
Total equity	248,945	1,543,213	1,439,996
Commitments and contingencies
Total liabilities and equity	$ 664,539	4,119,486	3,631,022

Consolidated Balance Sheets (Parenthetical) In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015 USD ($)	Mar. 31, 2015 CNY	Mar. 31, 2014 USD ($)	Mar. 31, 2014 CNY
Consolidated Balance Sheets
Accounts receivable, allowance for doubtful accounts	$ 4,618	28,624		20,322
Non-current accounts receivable, allowance for doubtful accounts	$ 8,906	55,211		42,703
Ordinary shares, par value per share	$ 0.0001		$ 0.0001
Ordinary shares, shares authorized	250,000,000	250,000,000	250,000,000	250,000,000
Ordinary shares, shares issued	73,140,147	73,140,147	73,140,147	73,140,147
Ordinary shares, shares outstanding	73,003,248	73,003,248	73,003,248	73,003,248
Treasury stock, shares	136,899	136,899	136,899	136,899

Consolidated Statements of Comprehensive Income In Thousands, except Per Share data, unless otherwise specified	12 Months Ended
	Mar. 31, 2015 USD ($)	Mar. 31, 2015 CNY	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY
Consolidated Statements of Comprehensive Income
Revenues	$ 102,456	635,122	572,857	526,123
Direct costs	(21,070)	(130,611)	(106,225)	(106,621)
Gross profit	81,386	504,511	466,632	419,502
Operating expenses
Research and development	(1,598)	(9,907)	(9,773)	(8,459)
Sales and marketing	(20,637)	(127,927)	(112,689)	(93,684)
General and administrative	(21,242)	(131,681)	(112,244)	(108,045)
Total operating expenses	(43,477)	(269,515)	(234,706)	(210,188)
Operating income	37,909	234,996	231,926	209,314
Other expense, net
Interest income	2,944	18,252	16,870	15,064
Interest expense	(16,309)	(101,102)	(70,075)	(70,097)
Exchange (loss)/gain	(37)	(231)	80	(984)
Dividend income	378	2,344	9,911	4,685
Others	139	861	2,212	203
Total other expense, net	(12,885)	(79,876)	(41,002)	(51,129)
Income before income tax	25,024	155,120	190,924	158,185
Income tax expense	(7,635)	(47,327)	(58,398)	(38,543)
Net income	17,389	107,793	132,526	119,642
Net income attributable to non-controlling interests	(81)	(501)	(623)	(7,195)
Net income attributable to China Cord Blood Corporation's shareholders	17,308	107,292	131,903	112,447
Net income per share: Attributable to ordinary shares
Basic	$ 0.22	1.36	1.60	1.49
Diluted	$ 0.22	1.36	1.60	1.49
Other comprehensive income
Net effect of foreign currency translation, net of nil tax	749	4,642	8,299	1,296
Net unrealized (loss)/gain in available-for-sale equity securities, net of nil tax	(4,142)	(25,675)	57,708	(9,120)
Comprehensive income	13,996	86,760	198,533	111,818
Comprehensive income attributable to non-controlling interests	(81)	(501)	(623)	(7,172)
Comprehensive income attributable to China Cord Blood Corporation's shareholders	$ 13,915	86,259	197,910	104,646

Consolidated Statement of Changes in Equity In Thousands, except Share data	Share capital USD ($)	Share capital CNY	Additional paid-in Capital USD ($)	Additional paid-in Capital CNY	Treasury stock USD ($)	Treasury stock CNY	Accumulated other comprehensive income USD ($)	Accumulated other comprehensive income CNY	Retained earnings USD ($)	Retained earnings CNY	Non-controlling interests USD ($)	Non-controlling interests CNY	Total USD ($)	Total CNY
Balance at Mar. 31, 2012		50		865,654				26,057		310,973		32,893		1,235,627
Balance, shares at Mar. 31, 2012		73,140,147												73,140,147
Net income										112,447		7,195		119,642
Other comprehensive income								(7,801)				(23)		(7,824)
Repurchase of shares						(131,302)								(131,302)
Repurchase of shares, shares						(7,450,914)								(7,450,914)
Sale of treasury shares				3,341		128,487								131,828
Sale of treasury shares, shares						7,314,015								7,314,015
Acquisition of non-controlling interests				(70,774)								(35,734)		(106,508)
Balance at Mar. 31, 2013		50		798,221		(2,815)		18,256		423,420		4,331		1,241,463
Balance, shares at Mar. 31, 2013		73,140,147				(136,899)								73,003,248
Net income										131,903		623		132,526
Other comprehensive income								66,007						66,007
Balance at Mar. 31, 2014		50		798,221		(2,815)		84,263		555,323		4,954		1,439,996
Balance, shares at Mar. 31, 2014		73,140,147				(136,899)								73,003,248
Net income										107,292		501	17,389	107,793
Other comprehensive income								(21,033)						(21,033)
Share-based compensation				16,457										16,457
Balance at Mar. 31, 2015	$ 8	50	$ 131,420	814,678	$ (454)	(2,815)	$ 10,200	63,230	$ 106,891	662,615	$ 880	5,455	$ 248,945	1,543,213
Balance, shares at Mar. 31, 2015	73,140,147				(136,899)								73,003,248

Consolidated Statements of Cash Flows In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2015 USD ($)	Mar. 31, 2015 CNY	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY
Operating activities:
Net income	$ 17,389	107,793	132,526	119,642
Adjustments to reconcile net income to net cash provided by operating activities:
Loss/(gain) on disposal of property, plant and equipment	4	23	(32)	1,066
Depreciation of property, plant and equipment	7,419	45,988	32,444	31,253
Amortization of intangible assets	745	4,621	4,621	4,621
Deferred income taxes	(147)	(912)	8,398	(194)
Provision for doubtful accounts	4,040	25,042	17,973	7,468
Interest on convertible notes	7,003	43,412	13,835	26,791
Amortization of debt issuance costs	582	3,610	3,610	3,062
Share-based compensation	2,667	16,535
Unrealized gain on trading securities	(32)	(201)
Changes in operating assets and liabilities:
Non-current deposits	2	12	261	1,513
Trading securities	(1,215)	(7,531)		354
Accounts receivable	(3,109)	(19,273)	(16,296)	3,334
Inventories	(332)	(2,059)	(29,973)	(8,678)
Prepaid expenses and other receivables	2,809	17,410	(25,441)	(3,470)
Accounts payable	363	2,251	532	3,547
Accrued expenses and other payables	45	276	11,036	42,080
Deferred revenue	48,263	299,186	317,767	289,942
Other non-current liabilities	8,342	51,718	56,745	46,380
Amounts due to related parties	(88)	(545)	10,421	10,881
Income tax payable	1,211	7,510	(2,412)	(960)
Net cash provided by operating activities	95,961	594,866	536,015	578,632
Investing activities:
Purchase of property, plant and equipment	(6,097)	(37,797)	(150,093)	(226,241)
Investment deposit				(213,160)
Proceeds from disposal of property, plant and equipment	2	13	210	450
Acquisition of other investment				(54,766)
Acquisition of available-for-sale equity securities	(750)	(4,647)
Net cash used in investing activities	(6,845)	(42,431)	(149,883)	(493,717)
Financing activities:
Repayment of bank loan	(9,679)	(60,000)	(50,000)	(45,000)
Proceeds from bank loan	9,679	60,000	60,000	50,000
Payment for repurchase of shares			(4,422)	(126,819)
Net proceeds from sale of treasury stock and acquisition of non-controlling interests				25,320
Proceeds from issuance of convertible notes				730,493
Payments for debt issuance costs			(3,242)	(15,276)
Net cash provided by financing activities			2,336	618,718
Effect of foreign currency exchange rate change on cash and cash equivalents	213	1,319	334	(3,845)
Net increase in cash and cash equivalents	89,329	553,754	388,802	699,788
Cash and cash equivalents at beginning of year	303,743	1,882,901	1,494,099	794,311
Cash and cash equivalents at end of year	393,072	2,436,655	1,882,901	1,494,099
Non-cash investing and financing activities:
Payable for property, plant and equipment			41,055	1,675
Payable for share repurchases				4,483
Payable for debt issuance costs				3,242
Supplemental disclosures of cash flow information:
Cash paid during the year for income taxes	7,620	47,234	64,683	40,105
Cash refund during the year for income taxes	2,969	18,404	429	408
Cash paid for interest, net of capitalized interest	$ 8,048	49,892	28,096	3,512

Principal activities, reorganization and reverse recapitalization, and basis of presentation	12 Months Ended
	Mar. 31, 2015
Principal activities, reorganization and reverse recapitalization, and basis of presentation
Principal activities, reorganization and reverse recapitalization, and basis of presentation	1Principal activities, reorganization and reverse recapitalization, and basis of presentation (a)Principal activities China Cord Blood Corporation (the “Company”) and its subsidiaries (collectively the “Group”) are principally engaged in the provision of umbilical cord blood storage and ancillary services in the People’s Republic of China (the “PRC”). As of March 31, 2015, the Group has three operating cord blood banks in the Beijing municipality, the Guangdong province and the Zhejiang province, the PRC. The Company’s shares are listed on the New York Stock Exchange. The Group provides cord blood testing, processing and storage services under the direction of subscribers for a cord blood processing fee and a storage fee. The Group also tests, processes and stores donated cord blood, and provides matching services to the public for a fee. The operation of cord blood banks in the PRC is regulated by certain laws and regulations. Cord blood banks in the PRC are required to possess a Blood Station Operation License. The licensing process for a cord blood bank is stringent and lengthy. The government authorities grant Blood Station Operation Licenses to cord blood banks that provide cord blood banking services. Cord blood banks collecting cord blood units from donors and providing matching cord blood units to the public without a duly obtained Blood Station Operation License face the risk of being shut down by the government. Seven cord blood banking licenses have been issued by the authorities as of March 31, 2015, of which the Company holds three. Due to the lack of a consistent and well-developed regulatory framework, operation in the cord blood banking industry in the PRC involves significant ambiguities, uncertainties and risks. The industry is highly regulated and any unilateral changes in regulations by the authorities may have a significant adverse impact on the Group’s results of operations. (b)Reorganization and reverse recapitalization The Company was previously named Pantheon China Acquisition Corp. (“Pantheon”), a blank check company whose objective was to acquire, through a stock exchange, asset acquisition or other similar business combination, an operating business that has its principal operations located in the PRC, or control such operating business through contractual arrangements. On November 3, 2008, China Cord Blood Services Corporation (“CCBS”) and its shareholders executed a Share Exchange Agreement with the Company. Pursuant to the Share Exchange Agreement, shareholders of CCBS were entitled to exchange their shares in CCBS for up to 57,851,240 shares of common stock of the Company. Shareholders holding 100% and 76% of CCBS’s ordinary shares and redeemable ordinary shares (collectively the “Participating Shareholders”), respectively, executed the Share Exchange Agreement and agreed to sell their 93.94% equity interests in CCBS to the Company for a consideration of US$328,790 in exchange for 54,345,104 shares of common stock of the Company (valued at US$6.05 per share of common stock) (the “Share Exchange”). The Share Exchange was approved at the Company’s special meeting of shareholders held on June 29, 2009 and was completed on June 30, 2009. Upon completion of the Share Exchange, the Company was renamed China Cord Blood Corporation and the Company was redomiciled to the Cayman Islands. The 54,345,104 shares of common stock of the Company held by the Participating Shareholders represent 91.7% of the then outstanding shares of the Company upon completion of the Share Exchange. Further, management of CCBS continued as the majority of the senior management of the Company upon completion of the Share Exchange. CCBS was therefore treated as the accounting acquirer in the Share Exchange. Prior to the Share Exchange, the Company did not operate a business. The Share Exchange was thus accounted for as the issuance of securities by CCBS in exchange for the assets and liabilities of Pantheon, accompanied by a recapitalization to utilize the share structure of Pantheon as the legal acquirer. In August 2009, the Company entered into agreements to exchange 3,506,136 of its newly issued ordinary shares for the remaining 24% of redeemable shares of CCBS held by shareholders who previously elected not to participate in the Share Exchange, on terms substantially similar to those of the Share Exchange. Upon the completion of such exchange, all the remaining redeemable ordinary shares of CCBS converted into ordinary shares of the Company, which carry no redemption rights, and CCBS became a wholly owned subsidiary of the Company. CCBS was incorporated in the Cayman Islands in January 2008 under the Cayman Islands Companies Law as an exempted company with limited liability. CCBS was incorporated as part of the reorganization of China Stem Cells Holdings Limited (“CSC Holdings”), which had two main operating subsidiaries in the PRC, Beijing Jiachenhong Biological Technologies Co., Ltd. (“Beijing Jiachenhong”) and Guangzhou Municipality Tianhe Nuoya Bio-engineering Co., Ltd. (“Guangzhou Nuoya”) at the time of the reorganization. Beijing Jiachenhong was established under the laws of the PRC in June 2001 as a domestic limited liability company. It became a Sino-Foreign Investment Enterprise in September 2003 and became a Wholly Foreign Owned Enterprise (“WFOE”) in March 2005. Beijing Jiachenhong is engaged in the provision of umbilical cord blood storage and ancillary services in the Beijing municipality, the PRC. In May 2007, China Stem Cells (South) Company Limited (“CSC South”), a then 90% subsidiary of the Company, acquired the entire equity interest of Guangzhou Nuoya for consideration of RMB30,949. Guangzhou Nuoya was established under the laws of the PRC in June 1997 as a domestic limited liability company. It became a WFOE in May 2007. Guangzhou Nuoya has been granted the right to operate cord blood banks in the Guangdong province, the PRC. In November 2012, CSC South repurchased 10% of its shares from Cordlife (Hong Kong) Limited, a subsidiary of Cordlife Group Limited (“CGL”), at a consideration of US$16,800. The shares repurchased were subsequently cancelled. The difference between the consideration paid and the carrying amount of non-controlling interest equal to RMB70,774 at the repurchase date was charged to additional paid-in capital. Concurrently, CGL acquired 7,314,015 shares, which were held by the Company as treasury stock (representing 10% of the Company’s ordinary shares at the time of the transaction) at a consideration of US$20,800. The difference between the consideration received from sale of the shares over the cost of the treasury shares equal to RMB3,341 was credited to additional paid-in capital. As a result, the Company received a net proceed of US$4,000 (RMB25,320) from the above two transactions and CSC South and its subsidiary became wholly owned subsidiaries of the Company. In December 2010, a non-wholly owned subsidiary, Zhejiang Lukou Biotechnology Co., Ltd. (“Zhejiang Lukou”), was established. The Group holds a 90% equity interest in Zhejiang Lukou through capital injection of RMB45,000, while the non-controlling shareholders contributed plant and equipment with fair value of RMB5,000 in return for the remaining 10% equity interests. In February 2011, the Group acquired the right to operate the cord blood bank in the Zhejiang province, the PRC, from a third party at a consideration of US$12,500 (equivalent to RMB82,124 (Note 8)). (c)Basis of presentation The accompanying consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”). This basis of accounting differs in certain material respects from that used for the preparation of the statutory books of the Company’s consolidated subsidiaries, which are prepared in accordance with the accounting principles and the relevant financial regulations applicable in the place of domicile of the respective entities in the Group. The accompanying consolidated financial statements reflect necessary adjustments not recorded in the statutory books of account of the Company’s consolidated subsidiaries to present them in conformity with U.S. GAAP.

Summary of significant accounting policies

12 Months Ended

Mar. 31, 2015

Summary of significant accounting policies

Summary of significant accounting policies

2Summary of significant accounting policies

(a)Principles of consolidation

The accompanying consolidated financial statements include the financial statements of the Company and its majority-owned subsidiaries. For consolidated subsidiaries where the Company’s ownership is less than 100%, the outside shareholders’ interests are shown as non-controlling interests. All significant intercompany balances and transactions have been eliminated in consolidation. The Company has no involvement with variable interest entities.

(b)Use of estimates

The preparation of the consolidated financial statements, in accordance with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include the establishment of the selling prices of multiple deliverables in revenue arrangements, the estimation of direct costs for the provision of donated cord blood for transplantation and research, the useful lives of property, plant and equipment and intangible assets, the valuation allowances for receivables and deferred tax assets, the realizability of inventories and the fair values of share-based compensation.

(c)Foreign currency transactions and translation

The reporting currency of the Company is Renminbi (“RMB”).

The functional currency of Beijing Jiachenhong, Guangzhou Nuoya and Zhejiang Lukou is RMB and the functional currency of the Company is United States dollars (“US$”). The functional currencies of subsidiaries of the Company outside the PRC are either US$ or Hong Kong dollars.

Transactions of Beijing Jiachenhong, Guangzhou Nuoya and Zhejiang Lukou denominated in currencies other than RMB are translated into RMB at the exchange rates quoted by the People’s Bank of China (the “PBOC”) prevailing at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies are translated into RMB using the applicable exchange rates quoted by the PBOC at the balance sheet date. The resulting exchange differences are recorded in the consolidated statements of comprehensive income.

Transactions of the Company and subsidiaries outside the PRC denominated in currencies other than their functional currencies are translated into their functional currencies at the exchange rates prevailing at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies are translated into their functional currencies using the applicable exchange rates at the balance sheet date. The resulting exchange differences are recorded in the consolidated statements of comprehensive income.

Assets and liabilities of the Company and subsidiaries outside the PRC are translated into RMB using the exchange rate at the balance sheet date. Revenues and expenses are translated at the average exchange rates prevailing during the year. The adjustments resulting from translation of financial statements of the Company and subsidiaries outside the PRC are recorded as a separate component of accumulated other comprehensive income within shareholders’ equity.

RMB is not a fully convertible currency. All foreign exchange transactions involving RMB must take place either through the PBOC or other institutions authorized to buy and sell foreign exchange. The exchange rates adopted for the foreign exchange transactions are the rates of exchange quoted by the PBOC, which are determined largely by supply and demand.

For the convenience of the readers, certain amounts as of and for the year ended March 31, 2015 included in the accompanying consolidated financial statements have been translated into U.S. dollars at the rate of US$1.00 = RMB6.1990, being the spot exchange rate of U.S. dollars in effect on March 31, 2015 for cable transfers in RMB per U.S. dollar as certified for customs purposes by the Federal Reserve, the central bank of the United States of America. No representation is made that the RMB amounts could have been, or could be, converted into U.S. dollars at that rate or at any other rate on March 31, 2015 or at any other date.

(d)Cash and cash equivalents

Cash and cash equivalents include short-term, highly liquid investments with original maturities of three months or less. Cash and cash equivalents of the Group are mainly maintained in the PRC and are denominated in several currencies. As of March 31, 2014 and 2015, cash and cash equivalents maintained in the PRC amounted to RMB1,812,007 and RMB2,261,306 (US$364,786), respectively. The Group’s cash and cash equivalents denominated in U.S. dollars, Australian dollars, Renminbi, Hong Kong dollars and Singapore dollars are as follows:

	March 31,
	2014		2015
	Foreign currency	RMB	Foreign currency	RMB

U.S. dollars	398	2,474	28,168	173,419
Australian dollars	242	1,378	1	5
Renminbi	1,812,025	1,812,025	2,261,327	2,261,327
Hong Kong dollars	81,188	64,503	2,361	1,863
Singapore dollars	515	2,521	9	41

Cash and cash equivalents held at financial institutions located in the PRC are uninsured, whereas cash held at financial institutions in Hong Kong are insured up to certain amount. Management believes that these major financial institutions have high credit ratings.

(e)Investment securities

Management determines the appropriate classification of its investment securities at the time of purchase and reevaluates such designations at each reporting date.

Trading securities are recorded at fair value. Unrealized holding gains and losses, net of the related tax effect, on trading securities are included in earnings.

Available-for-sale equity securities are recorded at fair value. Unrealized holding gains and losses, net of the related tax effect, on available-for-sale equity securities are excluded from earnings and are reported as a separate component of accumulated other comprehensive income until realized. Realized gains and losses from the sale of available-for-sale equity securities are determined on a specific-identification basis. Where the fair value of an investment in equity securities is not readily determinable, the investment is stated at cost.

A decline in the market value of available-for-sale securities that is deemed to be other-than-temporary results in an impairment to reduce the carrying amount to fair value. The impairment is charged to earnings and a new cost basis for the security is established. In determining whether an impairment is other-than-temporary, the Company considers whether it has the ability and intent to hold the investment until a market price recovery and considers whether evidence indicating the cost of the investment is recoverable outweighs evidence to the contrary. Evidence considered in this assessment includes the reasons for the impairment, the severity and duration of the impairment, forecasted performance of the investee, and the general market condition in the geographic area or industry the investee operates in.

Dividend income is recognized in other income when earned.

(f)Accounts receivable

Accounts receivable represent amounts due from subscribers for cord blood processing and storage services, which are recognized in accordance with the Company’s revenue recognition policies (Note 2(k)). Installments receivable from subscribers which are due for repayment in over one year under the deferred payment option are classified as non-current accounts receivable. Accounts receivable are stated net of allowance for doubtful accounts.

The allowance for doubtful accounts is the Group’s best estimate of the amount of estimated losses in the Group’s existing accounts receivable. The Group determines the allowance based on historical write-off experience, customer specific facts and economic conditions.

The Group reviews its allowances for doubtful accounts quarterly. Outstanding account balances are reviewed on a pooled basis by ageing of such balances. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Group’s PRC subsidiaries are required to comply with local tax requirements on the write-offs of doubtful accounts, which allow for such write-offs only when the related account balances are aged over three years and sufficient evidence is available to prove the debtor’s inability to make payments. For financial reporting purposes, the Company’s PRC subsidiaries generally record write-offs of doubtful accounts at the same time the local tax requirements for the write-offs are met. As a result, there are generally time lags between the time when a provision for doubtful accounts is recorded and the time the doubtful accounts are written off against the related allowance. The Group does not have any off-balance-sheet credit exposure related to its customers.

(g)Inventories

The Group collects, tests, freezes and stores donated umbilical cord blood for future transplantation or research purposes in return for a fee. Collection, testing and processing costs attributable to the processing of donated umbilical cord blood are capitalized as inventories, stated at the lower of cost or market on a weighted-average basis, and recognized as direct costs when revenue is recognized upon shipment of the donated cord blood units. Cost comprises direct materials, direct labor and an allocation of production overheads. Inventories that are not expected to be realized within 12 months from the balance sheet date are classified as non-current assets. Consumables and supplies are classified as current assets.

(h)Property, plant and equipment

Property, plant and equipment are stated at cost less accumulated depreciation.

Depreciation on property, plant and equipment is calculated based on the straight-line method (after taking into account their respective estimated residual values) over the estimated useful lives of the assets as follows:

Buildings		37.5 — 50 years
Leasehold improvements		Shorter of the lease term or estimated useful lives of 10 years
Machineries		5 — 10 years
Motor vehicles		5 years
Furniture, fixtures and office equipment		3 — 5 years

No depreciation expense is provided in respect of construction-in-progress.

Interest expense incurred related to the construction of property, plant and equipment is capitalized. The capitalization of interest expense as part of the cost of a qualifying asset commences when expenditures for the asset have been made, activities that are necessary to get the asset ready for its intended use are in progress and interest cost is being incurred. The capitalization period ends when the asset is substantially complete and ready for its intended use.

Depreciation of property, plant and equipment attributable to the processing of donated umbilical cord blood for future transplantation is capitalized as part of inventories, and is expensed to direct costs upon shipment of the donated cord blood units.

(i)Intangible assets

Intangible assets represent the operating rights to operate cord blood bank and are stated at the fair value on the date of acquisition less accumulated amortization. Where payment for an operating right is non-deductible for tax purpose, the simultaneous equations method is used to record the assigned value of the asset and the related deferred tax liability, such that the carrying amount of the asset upon initial recognition less deferred tax liability recognized equals the amount paid for the asset. Amortization expenses are recognized on a straight-line basis over the estimated useful life of the operating rights of 30 years.

Given the environment in which the Group currently operates, it is reasonably possible that the estimated economic useful life of the assets or the Group’s estimate that it will recover its carrying amount from future operations could change in the future.

(j)Impairment of long-lived assets

Long-lived assets, including property, plant and equipment and intangible assets with finite useful lives, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset or asset group to the estimated undiscounted future cash flows expected to be generated by the asset or asset group. If the carrying amount of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying amount exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flows models, quoted market values and third-party independent appraisals, as considered necessary. No impairment of long-lived assets was recognized for the years ended March 31, 2013, 2014 and 2015.

(k)Revenue recognition

The Group receives fees for collecting, testing, freezing and storing of cord blood units. Once the cord blood units are collected, tested, screened and successfully meet all of the required attributes, the Group freezes the units and stores them in a cryogenic freezer. Under the cord blood processing and storage agreement (“Agreement”) signed with the customer, the Group charges separate processing fee and storage fees to the customer and such Agreement typically provides for a storage period of eighteen years represented by successive one-year renewal periods. The Group also arranges an insurance policy for customers. The amount of gross storage fees include insurance premiums collected on behalf of a third-party insurance company. The amount attributable to the insurance premiums is included in current and non-current other payables and is not recognized as revenue. The Group has no performance obligation to the customer with respect to the insurance policy.

The Agreement is a multiple-element arrangement, which includes (i) the processing of cord blood unit and (ii) the storage of cord blood unit. The Group accounts for the arrangement under the ASC 605-25, Revenue Recognition — Multiple-Element Arrangements. In accordance with ASC 605-25, revenue arrangements that include multiple elements are analyzed to determine whether the deliverables can be divided into separate units of accounting or treated as a single unit of accounting. The consideration received is allocated among the separate units of accounting based on their relative selling prices determined based on prices of these elements as sold on a stand-alone basis, and the applicable revenue recognition criteria are applied to each of the separate units. In an arrangement with multiple deliverables, the delivered product or service shall be considered a separate unit of accounting when the following criteria are met: (1) the delivered item or items have value to the customer on a standalone basis; and (2) if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item or items is considered probable and substantially in the control of the Group. Based on evaluation of the criteria, the Group has determined that the cord blood processing services and cord blood storage services are to be accounted for as separate units.

Pursuant to the Agreement, no penalty is charged to customers for early termination of the cord blood storage service.

The Group considers all reasonably available information to allocate the overall arrangement fee to cord blood processing and cord blood storage services based on their relative selling prices.

The Group recognizes processing fee revenue upon successful completion of processing services and when the cord blood unit meets all the required attributes for storage, and recognizes the storage fee revenues ratably over the annual storage period.

During the years ended March 31, 2013, 2014 and 2015, the Group offered its customers three payment options:

(i)Payment of the processing fee upon delivery of the cord blood unit to the Group’s premises for processing and the annual storage fee in advance at the beginning of each one-year renewal period;

(ii)Payment of the processing fee upon delivery of the cord blood unit to the Group’s premises for processing and an upfront payment of storage fees for a period of eighteen years; and

(iii)Payment of the processing fee by installment over multiple periods and the annual storage fee in advance at the beginning of each one-year renewal period or an upfront payment of storage fees for a period of eighteen years paid by four installments. Certain installment option includes an initial processing fee payment upon delivery of the cord blood unit to the Group’s premises for processing and an incremental annual payment for the consecutive periods, representing a surcharge to the total amount of processing fees payable under payment options (i) and (ii).

Under payment option (iii), installments due for payment beyond one year are classified as non-current accounts receivable. The surcharge payable by customers under the installment plan is recognized as interest income using the effective interest method.

The recognition of storage revenue is ceased when the collectability of the storage fees from the customers is not reasonably assured due to delinquency of payment by the customers. During the years ended March 31, 2013, 2014 and 2015, the Group ceased recognizing storage revenue from subscribers who were delinquent for more than 24 months.

According to the notice jointly issued by the Ministry of Finance and the State Administration of Taxation in November 2011, the taxable service revenue provided by the Group’s three main PRC subsidiaries is subject to Value-Added Tax (“VAT”). Beijing Jiachenhong, Guangzhou Nuoya and Zhejiang Lukou are subject to VAT effective for periods starting from September 1, 2012, November 1, 2012 and December 1, 2012, respectively. VAT at a general rate of 6% on the invoiced amount is collected on behalf of tax authorities in respect of the services rendered. Prior to those periods, the Group’s three main PRC subsidiaries were subject to business tax at a general rate of 5% of service revenues. Revenue is stated net of VAT or business tax.

(l)Research and development costs

Research and development costs are incurred for research activities conducted to enhance operating efficiencies, collection and storage technologies, and measures to improve the results in umbilical cord blood stem cells extraction and separation. They also include research expenses on the use of cord blood stem cells in different medical treatments. Research and development costs are expensed as incurred.

(m)Advertising and promotion costs

Advertising and promotion costs are expensed as incurred. Advertising and promotion costs included in sales and marketing expenses in the consolidated statements of comprehensive income amounted to RMB19,215, RMB30,785 and RMB30,899 (US$4,985) for the years ended March 31, 2013, 2014 and 2015, respectively.

(n)Retirement and other postretirement benefits

Contributions to retirement schemes (which are defined contribution plans) are charged to the consolidated statements of comprehensive income when the related employee service is provided. The Group does not have any defined benefit retirement plans.

(o)Debt issuance costs

Costs incurred by the Company that are directly attributable to the issuance of the convertible notes are deferred and charged to the consolidated statements of comprehensive income using an effective interest rate method from the date the convertible notes were issued to the earliest date the holders of the convertible notes can demand payment, which is five years.

(p)Income taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases, tax loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided to reduce the amount of deferred tax assets if it is considered more likely than not that some portion or all of the deferred tax assets will not be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the consolidated statements of comprehensive income in the period that includes the enactment date.

The Group recognizes in the consolidated financial statements the impact of a tax position if that position is more likely than not of being sustained upon examination, based on the technical merits of the position. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Group has elected to classify interest and penalties related to unrecognized tax benefits, if and when required, as part of income tax expense in the consolidated statements of comprehensive income.

A deferred tax liability is not recognized for the excess of the Company’s financial statements carrying amount over the tax base of its investment in a foreign subsidiary, if the subsidiary has invested or will invest the undistributed earnings indefinitely.

(q)Commitments and contingencies

In the normal course of business, the Group is subject to contingencies, including legal proceedings and claims that relate to a wide range of matters, including, among others, product liability. The Group records accruals for such contingencies based upon the assessment of the probability of occurrence and, where determinable, an estimate of the liability. The Group may consider many factors in making these assessments including past history and the specifics of each matter.

(r)Earnings per share

Basic earnings per ordinary share is computed by dividing net income attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the year using the two-class method. Under the two-class method, net income attributable to common shareholders is allocated between ordinary shares and participating securities based on contractual participating rights of security to share in undistributed earnings as if all of the earnings had been distributed.

Diluted earnings per share is computed by dividing net income attributable to ordinary shareholders, as adjusted to exclude any income or expenses related to dilutive ordinary equivalents shares by the weighted average number of ordinary shares and dilutive potential ordinary shares outstanding during the period. Dilutive potential ordinary shares consist of the ordinary shares issuable upon the exercise of outstanding share options by applying the treasury stock method and the ordinary shares issuable upon the conversion of the convertible notes applying the if-converted method. Dilutive potential ordinary shares in the diluted earnings per share computation are excluded to the extent that their effect is anti-dilutive.

(s)Share-based compensation

The Group recognizes share-based payments as compensation cost and measures such cost based on the grant date fair value of the equity instrument issued. Compensation expense is recognized on a straight-line basis over the requisite service period, which is generally the same as the vesting period.

The service inception date is the date at which the requisite service period begins. The service inception date usually is the grant date; however the service inception date precedes the grant date if (a) an award is authorized, (b) service begins before a mutual understanding of the key terms and conditions of a share-based payment award is reached, and (c) either of the following conditions applies: (1) the award’s terms do not include a substantive future requisite service condition that exists at the grant date, or (2) the award contains a market or performance condition that if not satisfied during the service period preceding the grant date and following the inception of the arrangement results in forfeiture of the award. For the purpose of determining the service inception date, authorization of an award is the date on which all approval requirements are completed unless approval is perfunctory.

(t)Segment reporting

The Group has one operating segment, as defined by ASC 280, Segment Reporting, which is processing and storage of cord blood units. All of the Group’s operations and customers are located in the PRC. Consequently, no geographic information is presented.

(u)Fair value measurement

The Group utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Group determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:

Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.

Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.

Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.

See Note 22 to the consolidated financial statements.

(v)Recently issued accounting standards

In April 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity (“ASU 2014-08”), which changes the requirements for reporting discontinued operations. ASU 2014-08 limits discontinued operations reporting to disposals of components of an entity that represent strategic shifts that have a major effect on an entity’s operations and financial results. As a result, the Company expects to report fewer discontinued operations under the new standard than would otherwise be reported under previous requirements. ASU 2014-08 is effective for any disposals of components of the Company in annual reporting periods beginning after December 15, 2014, and interim periods within those years.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), which requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. An entity should also disclose sufficient quantitative and qualitative information to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2016.

In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements — Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”), which requires management to evaluate, at each annual and interim reporting period, whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date the financial statements are issued and to provide related disclosures. ASU 2014-15 is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter.

In January 2015, the FASB issued ASU 2015-01, Income Statement — Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items (“ASU 2015-01”), which eliminates the concept of reporting for extraordinary items. ASU 2015-01 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015.

In February 2015, the FASB issued ASU 2015-02, Consolidation (Topic 810): Amendments to the Consolidation Analysis (“ASU 2015-02”), which reduces the number of consolidation models and simplifies the current standard. Entities may no longer need to consolidate a legal entity in certain circumstances based solely on its fee arrangements when certain criteria are met. ASU 2015-02 reduces the frequency of the application of related-party guidance when determining a controlling financial interest in a variable interest entity. ASU 2015-02 is effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2015.

In April 2015, the FASB issued ASU 2015-03, Interest — Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs (“ASU 2015-03”), which requires entities to present debt issuance costs related to a recognized debt liability as a direct deduction from the carrying amount of that debt liability. ASU 2015-03 is effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years.

Accounts receivable, net

12 Months Ended

Mar. 31, 2015

Accounts receivable, net

Accounts receivable, net

3Accounts receivable, net

(a)Accounts receivable consist of the following:

	March 31,
	2014		2015		2015
	RMB		RMB		US$

Accounts receivable	383,794		398,835		64,338
Less: Allowance for doubtful accounts	(63,025	)	(83,835	)	(13,524	)

Total accounts receivable, net	320,769		315,000		50,814


Representing:

Current portion:
- Processing fees	64,838		78,911		12,729
- Storage fees	28,894		39,522		6,375
- Others	1,541		2,329		376

	95,273		120,762		19,480
Non-current portion:
- Processing fees	225,496		194,238		31,334

Total accounts receivable, net	320,769		315,000		50,814

Non-current gross accounts receivable as of March 31, 2015 are due for payment as follows:

	March 31, 2015
	RMB	US$
Fiscal years ending March 31,
2017	31,504	5,082
2018	30,874	4,980
2019	29,133	4,700
2020	29,558	4,768
2021 and thereafter	184,118	29,701

	305,187	49,231

(b)An analysis of the allowance for doubtful accounts is as follows:

	Year ended March 31,
	2013		2014		2015		2015
	RMB		RMB		RMB		US$

Balance at beginning of year	52,544		50,473		63,025		10,167
Charged to allowance for doubtful accounts	7,468		17,973		25,042		4,040
Write-off charged against the allowance for the year	(9,539	)	(5,421	)	(4,232	)	(683	)

Balance at end of year	50,473		63,025		83,835		13,524

The Group continuously monitors the recoverability of the accounts receivable, the credit quality of such receivables, the effectiveness and the efficiency of its collection efforts.

During the years ended March 31, 2013, 2014 and 2015, the Group wrote-off accounts receivable of RMB9,539, RMB5,421 and RMB4,232 (US$683), which were aged over three years since there was sufficient evidence available to prove the debtor’s inability to make payments.

Inventories

12 Months Ended

Mar. 31, 2015

Inventories

Inventories

4Inventories

Inventories consist of the following:

	March 31,
	2014	2015	2015
	RMB	RMB	US$

Current portion:
- Consumables and supplies	31,583	23,803	3,840

Non-current portion:
- Processing costs capitalized in donated umbilical cord blood	48,385	58,224	9,392


Total current and non-current inventories	79,968	82,027	13,232

Collection, testing and processing costs attributable to the processing of donated umbilical cord blood are capitalized as inventories. Management assesses the recoverability of such inventories with reference to future projections of matching fees, number of donated cord blood units of the Group, demand for cord blood units for transplantation and research purposes, and the probability of finding a match in light of the number of units held. Based on such assessments, the management considers that the cord blood processing costs capitalized are recoverable and no provision for inventories was made during the years ended March 31, 2013, 2014 and 2015.

The Group recognizes the revenue for one matched donated umbilical cord blood unit upon shipment of the unit and recognizes the cost of the cord blood unit equal to the carrying amount of the total inventory (donated umbilical cord blood units) divided by the estimated future number of successful matches which would become realized through sales during the estimated weighted average remaining useful life of the donated umbilical cord blood unit. As of March 31, 2015, the weighted average remaining useful life of the donated umbilical cord blood units was estimated to be approximately 19 years. Based on the historical increase in the number of donated umbilical cord blood matching inquiries and the number of successful matches of donated umbilical cord blood units, the Group estimated the number of successful matches of donated umbilical cord blood units will increase by 7% per annum. There were no material changes to the estimates and assumptions underlying the methodology for the years ended March 31, 2013, 2014 and 2015.

Prepaid expenses and other receivables

12 Months Ended

Mar. 31, 2015

Prepaid expenses and other receivables

Prepaid expenses and other receivables

5Prepaid expenses and other receivables

Prepaid expenses and other receivables consist of the following:

	March 31,
	2014	2015	2015
	RMB	RMB	US$

Prepaid expenses	20,593	14,326	2,311
Tax receivables	13,406	548	88
Other receivables	3,011	4,634	748

Total prepaid expenses and other receivables	37,010	19,508	3,147

Other receivables mainly include advance payments to employees and rental deposits.

Property, plant and equipment, net

12 Months Ended

Mar. 31, 2015

Property, plant and equipment, net

Property, plant and equipment, net

6Property, plant and equipment, net

Property, plant and equipment, net consist of the following:

	March 31,
	2014		2015		2015
	RMB		RMB		US$

Buildings	578,513		581,252		93,766
Leasehold improvements	14,864		14,864		2,398
Machineries	118,449		137,811		22,231
Motor vehicles	14,885		15,209		2,453
Furniture, fixtures and equipment	35,433		40,132		6,474
Construction-in-progress	9,684		4,283		691

	771,828		793,551		128,013
Less: Accumulated depreciation	(145,196	)	(190,384	)	(30,712	)

Total property, plant and equipment, net	626,632		603,167		97,301

Depreciation expense of property, plant and equipment is allocated to the following expense items:

	Year ended March 31,
	2013	2014	2015	2015
	RMB	RMB	RMB	US$

Direct costs	17,421	18,150	28,819	4,649
Research and development	2,073	1,863	2,231	360
Sales and marketing	2,805	2,611	2,530	408
General and administrative	8,954	9,820	12,408	2,002

Total depreciation expense	31,253	32,444	45,988	7,419

Interest cost incurred consists of the following:

	Year ended March 31,
	2013	2014	2015	2015
	RMB	RMB	RMB	US$

Interest cost capitalized	1,274	25,912	—	—
Interest cost charged to income	70,097	70,075	101,102	16,309

Total interest cost incurred	71,371	95,987	101,102	16,309

As of March 31, 2014 and 2015, buildings with carrying value of RMB114,570 and RMB107,509 (US$17,343) were collateralized for short-term bank loans of RMB60,000 and RMB60,000 (US$9,679), respectively (Note 11).

Non-current deposits

12 Months Ended

Mar. 31, 2015

Non-current deposits

Non-current deposits

7Non-current deposits

Non-current deposits consist of the following:

		March 31,
	Note	2014	2015	2015
		RMB	RMB	US$

Investment deposit	(i)	208,591	207,226	33,429
Deposit for machineries purchase		303	32	5

Total non-current deposits		208,894	207,258	33,434

Note:

(i)

During the year ended March 31, 2013, the Group signed a Letter of Intent with a third party for a potential acquisition of the equity interests in a company in the healthcare industry and the Group remitted a refundable earnest money deposit of US$33,660 (RMB207,226) to this third party and commenced the relevant work with respect to the investment opportunity. As of the date of this report, the project is still on-going.

Intangible assets, net

12 Months Ended

Mar. 31, 2015

Intangible assets, net

Intangible assets, net

8Intangible assets, net

	March 31,
	2014		2015		2015
	RMB		RMB		US$

Cord blood bank operating rights	138,628		138,628		22,363
Less: Accumulated depreciation	(18,079	)	(22,700	)	(3,662	)

Total intangible assets, net	120,549		115,928		18,701

Intangible assets represent the cord blood bank operating rights in the Guangdong province and the Zhejiang province, the PRC.

The cord blood bank operating right in the Guangdong province was acquired through the acquisition of Guangzhou Nuoya in May 2007. The estimated useful life of the operating right is thirty years. Amortization expenses of the operating right in the Guangdong province were RMB971, RMB971 and RMB971 (US$157) for the years ended March 31, 2013, 2014 and 2015, respectively. The operating right is subject to renewal and the next renewal is due in May 2018.

In February 2011, the Group acquired the right to operate the cord blood bank in the Zhejiang province from a third party for cash consideration of US$12,500 (equivalent to RMB82,124) which was fully settled in August 2011. Payment for the operating right is non-deductible for tax purpose. The simultaneous equations method is used to record the assigned value of the asset of RMB109,499 and a related deferred tax liability of RMB27,375 (Note 17(c)), in accordance with the guidance in ASC 740-10-25-51, such that the carrying amount of the asset upon initial recognition less the related deferred tax liability equals the cash consideration paid. The estimated useful life of the Zhejiang operating right is thirty years. Amortization expenses were RMB3,650, RMB3,650 and RMB3,650 (US$588) for the years ended March 31, 2013, 2014 and 2015, respectively. The operating right is subject to renewal and the next renewal is due in September 2016.

The Group determined that a thirty-year period to amortize the cord blood bank operating rights was appropriate, following the pattern in which the expected benefits of the acquired asset will be consumed or otherwise used up. The Group’s renewal period with the provincial governmental authorities generally is for a period of three years. The Group has historically renewed cord blood bank operating rights without incurring any significant costs. There are no other legal or regulatory provisions that limit the useful life of the cord blood bank operating rights or that cause the cash flows and useful life of such cord blood bank operating right to be constrained. In addition, the Group expects the effect of obsolescence, demand, competition, and other economic factors to be minimal.

The Group engaged independent third party valuation firms in determining the fair values of the cord blood bank operating rights during the acquisitions. The fair values of the cord blood bank operating rights were determined using an income approach and considered assumptions (including turnover rate) that a market participant would make consistent with the highest and best use of the asset by market participants. The periods of expected cash flows used to measure the fair values of the cord blood bank operating rights were thirty years. Without evidence to the contrary, the Group expects that the cord blood bank operating rights will be renewed at the same rate as a market participant would expect, and no other factors would indicate a different useful life is more appropriate. Accordingly, in the absence of other entity-specific factors, the useful life of the cord blood bank operating rights was determined to be thirty years.

A straight-line method of amortization has been adopted as the pattern in which the economic benefits of the operating rights are used up cannot be reliably determined. Estimated amortization expenses for the years ending after March 31, 2015 are:

	March 31, 2015
	RMB	US$
Fiscal years ending March 31,
2016	4,621	745
2017	4,621	745
2018	4,621	745
2019	4,621	745
2020 and thereafter	97,444	15,721

Total amortization expenses	115,928	18,701

Available-for-sale equity securities

12 Months Ended

Mar. 31, 2015

Available-for-sale equity securities

Available-for-sale equity securities

9Available-for-sale equity securities

	March 31,
	2014	2015	2015
	RMB	RMB	US$

Life Corporation Limited - listed on Australian Securities Exchange	4,630	4,205	678
Cordlife Group Limited - listed on Singapore Exchange	139,617	118,211	19,070

Total listed equity securities, at market	144,247	122,416	19,748

During the year ended March 31, 2008, the Group acquired 11,730,000 ordinary shares of Cordlife Limited (“CBB”) at a total cost of RMB53,699. CBB was a provider of cord blood banking services with operations in Singapore, Hong Kong, India, Indonesia and the Philippines, and was listed on the Australian Securities Exchange. During the year ended March 31, 2009, the Group acquired an additional 5,795,000 ordinary shares of CBB at a total cost of RMB11,172, satisfied in cash. The Group further subscribed for 6,841,666 shares of CBB at a total cost of RMB13,245, satisfied in cash, during the year ended March 31, 2011. As of March 31, 2011, the Group held 24,366,666 ordinary shares of CBB.

On June 16, 2011, the shareholders of CBB approved a capital reduction by way of distribution in specie. The scheme involved a spin off of Cordlife Pte Ltd from CBB, and the shares of Cordlife Pte Ltd were distributed to the then shareholders of CBB on a pro rata basis. The restructuring and distribution in specie were completed and effective on June 30, 2011. After the restructuring of CBB as of June 30, 2011, the Group owned a total of 24,366,666 shares in each of CBB and Cordlife Pte Ltd, respectively. The Group’s original investment in CBB upon the completion of restructuring was recognized as two separate investments consisting of CBB and Cordlife Pte Ltd. The capital reduction or the distribution in specie by CBB did not constitute a sale of available-for-sale equity securities. The cost of both investments was determined based on their respective estimated fair values as of the restructuring date and adjusted by the unrealized holding gains of CBB recorded in accumulated other comprehensive income on pro rata basis. After the restructuring, Cordlife Pte Ltd was a private company, whose shares did not have a readily determinable fair value. The investment in Cordlife Pte Ltd was therefore accounted for by the cost method under ASC 325-20, before its listing on the Singapore Exchange on March 29, 2012.

In connection with a proposed listing on the Singapore Exchange, Cordlife Pte Ltd changed its name to CGL. On March 29, 2012, CGL was listed on the Singapore Exchange. Upon CGL’s listing on March 29, 2012, the Group accounted for its investment in CGL at fair value.

In July 2013, CBB changed its name to Life Corporation Limited (“LFC”) and in December 2013, LFC did a reverse stock split at the rate of 1 to 3.

As of March 31, 2014, the Group held 8,122,222 ordinary shares in LFC and 24,366,666 ordinary shares in CGL and the Group’s equity interest in LFC and CGL was 11.4% and 9.2%, respectively.

During the year ended March 31, 2015, the Group acquired an additional 1,150,000 ordinary shares of CGL at a total cost of RMB4,647 (US$750), satisfied in cash.

As of March 31, 2015, the Group held 8,122,222 ordinary shares in LFC and 25,516,666 ordinary shares in CGL and the Group’s equity interest in LFC and CGL was 11.4% and 9.8%, respectively.

In February and August 2014 respectively, CGL announced dividends of SGD0.01 per ordinary share relating to CGL’s fiscal year ended June 30, 2014 and the Group received dividends of SGD487 (equivalent to RMB2,344) during the year ended March 31, 2015. Dividends received from CGL during the years ended March 31, 2013, 2014 and 2015 of RMB4,685, RMB2,414 and RMB2,344 (US$378), respectively, were recorded in dividend income in the consolidated statements of comprehensive income.

As of March 31, 2014, the cost basis of the available-for-sale equity securities was RMB40,690. Total unrealized net holding losses of LFC was RMB6,527 and total unrealized net holding gains of CGL was RMB121,047. The aggregate fair values was RMB144,247 as of March 31, 2014.

As of March 31, 2015, the cost basis of the available-for-sale equity securities was RMB45,337 (US$7,314). Total unrealized net holding losses of LFC was RMB6,918 (US$1,116) and total unrealized net holding gains of CGL was RMB95,763 (US$15,448). The aggregate fair values was RMB122,416 (US$19,748) as of March 31, 2015.

The available-for-sale equity securities are held by a subsidiary whose functional currency is Hong Kong dollars. Both securities are traded in a foreign market. The fair values are based on the current market values of the securities and the current exchange rates between Hong Kong dollars and Australia dollars or Singapore dollars, as applicable. Both investments are translated into RMB, the Group’s reporting currency, using the exchange rate at the balance sheet dates.

The Group determined that the unrealized loss of LFC as of March 31, 2014 and 2015 was temporary. During the years ended March 31, 2014 and 2015, the market price of LFC was volatile. During the year ended March 31, 2014, the average monthly market price exceeded the cost basis of the investment. As of March 31, 2015, the length of time to which the market value of LFC was less than cost was less than six months.

Other investment

12 Months Ended

Mar. 31, 2015

Other investment

Other investment

10Other investment

	March 31,
	2014	2015	2015
	RMB	RMB	US$

Unlisted equity securities, at cost	189,129	189,129	30,510

In May 2010, the Group completed its acquisition of 19.92% equity interest of Shandong Province Qilu Stem Cells Engineering Co., Ltd. (“Qilu Stem Cells”), which operates a cord blood bank in the Shandong province, the PRC. The Group does not have significant influence over the financial and operating decisions of Qilu Stem Cells. The investment is stated at cost as the equity securities do not have a readily determinable fair value.

In February 2013, the Group completed its acquisition of 4.08% equity interest of Qilu Stem Cells from Cordlife Service (S) Pte. Ltd., a wholly owned subsidiary of CBB at the time of the acquisition, satisfied in cash of US$8,650 (RMB54,766). Upon completion of the transaction, the Group’s effective equity interest in Qilu Stem Cells increased from 19.92% to 24%. Although the Group increased its effective equity interest in Qilu Stem Cells to over 20%, the Group does not have any representation in the board of directors and does not have the ability to exert significant influence in Qilu Stem Cells. Accordingly, the investment in Qilu Stem Cells is accounted under the cost method as of March 31, 2014 and 2015.

Dividends declared and paid by Qilu Stem Cells during the year ended March 31, 2014 of RMB7,497 were recognized in dividend income in the consolidated statements of comprehensive income. No dividend was declared or paid by Qilu Stem Cells during the years ended March 31, 2013 and 2015.

Accrued expenses and other payables

12 Months Ended

Mar. 31, 2015

Accrued expenses and other payables

Accrued expenses and other payables

12Accrued expenses and other payables

Accrued expenses and other payables consist of the following:

		March 31,
	Note	2014	2015	2015
		RMB	RMB	US$

Insurance premium received on behalf of insurance company	(i)	15,292	20,035	3,233
Other tax payables		3,927	3,312	534
Accrued salaries, bonus and welfare expenses		23,005	21,026	3,392
Accrued consultancy and professional fees		3,599	3,287	530
Accrued interest on convertible notes	(ii)	26,188	26,017	4,197
Payable for property, plant and equipment		15,969	694	112
Other payables	(iii)	14,579	13,010	2,099

Total accrued expenses and other payables		102,559	87,381	14,097

Notes:

(i)	The Group has an agreement with an insurance company under which the Group is granted the authority to collect insurance premiums on behalf of the insurance company from customers who store umbilical cord blood in the Group’s cord blood bank and are enrolled in the insurance scheme offered by the insurance company. The insurance premiums amount collected and payable over one year are recorded in other non-current liabilities in the consolidated balance sheets.

(ii)	Accrued interest on convertible notes represents the interest accrued based on coupon interest rate of 7% of outstanding principle of convertible notes, which is to be settled annually on April 27 (Note 14).

(iii)	Other payables mainly include fee refundable to customers whose cord blood unit does not qualify for subsequent storage and other operating procurement payables.

Deferred revenue

12 Months Ended

Mar. 31, 2015

Deferred revenue

Deferred revenue

13Deferred revenue

(a)Deferred revenue consists of the following:

	March 31,
	2014	2015	2015
	RMB	RMB	US$

Payments by customers prior to completion of cord blood processing services	93,597	87,296	14,082
Unearned storage fees	926,756	1,232,243	198,781

Total current and non-current deferred revenue	1,020,353	1,319,539	212,863


Representing:
Current portion	196,432	220,140	35,512
Non-current portion	823,921	1,099,399	177,351

Total current and non-current deferred revenue	1,020,353	1,319,539	212,863

(b)An analysis of the unearned storage fees is as follows:

	Year ended March 31,
	2013		2014		2015		2015
	RMB		RMB		RMB		US$

Balance at beginning of year	361,034		608,115		926,756		149,501
Deferred revenue arising from new customers	376,536		485,290		509,334		82,164
Credited to income	(129,455	)	(166,649	)	(203,847	)	(32,884	)

Balance at end of year	608,115		926,756		1,232,243		198,781

Convertible notes

12 Months Ended

Mar. 31, 2015

Convertible notes

Convertible notes

14Convertible notes

On April 27, 2012, the Company completed the sale of US$65,000 in aggregate principal amount of 7% coupon interest rate senior unsecured convertible notes to KKR China Healthcare Investment Limited (“KKRCHIL”) (the “KKR Notes”). The KKR Notes are convertible into the Company’s ordinary shares at a conversion price of US$2.838 per share. The Company received gross proceeds of US$65,000 and incurred debt issuance costs of RMB14,260 from the issuance of the KKR Notes. The KKR Notes are senior unsecured obligations, maturing on April 27, 2017 and are not redeemable prior to their maturity at the Company’s option. The KKR Notes are convertible at any time in whole or in part, into the Company’s ordinary shares at the conversion price, subject to customary anti-dilution adjustments for significant corporate events. On the maturity date, the Company is obligated to pay a redemption amount on the unconverted portion of the KKR Notes that is calculated to provide a 12% Internal Rate of Return (“IRR”).

On October 3, 2012, the Company completed the sale of aggregate US$50,000 senior unsecured convertible notes to Golden Meditech Holdings Limited (“GMHL”), which is a major shareholder of the Company (the “GM Notes”). The GM Notes carry a 7% coupon interest rate and are convertible into the Company’s ordinary shares at a conversion price of US$2.838 per share. The Company received gross proceeds of US$50,000 and incurred debt issuance costs of RMB4,258 from the issuance of the GM Notes. The GM Notes are senior unsecured obligations, maturing on October 3, 2017 and are not redeemable prior to their maturity at the Company’s option. The GM Notes are convertible at any time in whole or part, into the Company’s ordinary shares at the conversion price, subject to customary anti-dilution adjustments for significant corporate events. On the maturity date, the Company is obligated to pay a redemption amount on the unconverted portion of the GM Notes that is calculated to provide a 12% IRR.

In November 2014, GMHL completed the sale of the GM Notes of US$50,000 in aggregate principal amount to Magnum Opus International Holdings Limited (“Magnum”), a private vehicle that is controlled by the Company’s chairman, and CGL, for a total consideration of US$88,090. As a result, the holders of the GM Notes became Magnum and CGL and each of them holds US$25,000 of the GM Notes. All terms and conditions of the GM Notes remain the same after the transfer from GMHL to Magnum and CGL, except for the change of holder name on the convertible notes and the denomination of the fair value of the convertible notes from US$50,000 to US$25,000.

The carrying amounts of each of the convertible notes as of March 31, 2014 and 2015 are summarized in the following table:

	March 31,
	2014	2015	2015
	RMB	RMB	US$

Principal amount of the KKR Notes	403,315	400,175	64,554
Principal amount of the GM Notes	310,302	307,828	49,658
Cumulative interest payables	64,136	107,848	17,398

Carrying amount	777,753	815,851	131,610

Holders of the KKR Notes and GM Notes (collectively the “Notes”) have the right to require the Company to redeem all or any portion of the Notes upon occurrence of events of default. Such events of default under the Notes include suspension from trading or failure of the Company’s ordinary shares to be listed over certain periods (subject to certain exceptions), failure to deliver ordinary shares upon conversion, or failure to pay principal or interest to the holder within certain periods when due and payable (including, without limitation, the Company’s failure to pay any redemption payments), bankruptcy, materially breaches of any covenants or terms in the Notes, the incurrence of any indebtedness of the Group and any final judgment or judgment against the Group exceeding certain amount, and any other event or events that could be expected to have material adverse effects on the Group. From and after the thirtieth day following the occurrence, and during the continuance, of an event of default under the Notes, the interest rate shall be increased to twenty-two and one-half percent (22.5%) per annum.

The Notes are entitled to a special redemption payment in the event the Group breaches certain covenants. The KKR Notes are also entitled to a special redemption payment in the event GMHL or certain members of the Company’s senior management violate the terms of certain lock-up agreements they have entered into in favor of KKRCHIL. The Notes contain customary ongoing covenants, including affirmative covenants and negative covenants. Covenants are set out in the convertible notes purchase agreement and/or the Notes, including but not limited to compliance with Securities and Exchange Commission filings and all applicable laws and rules; maintaining Form F-3 eligibility and maintaining and keeping all the current held cord blood banking licenses effective; the Company shall not, without the prior written consent of the holders of the Notes, change its principal business; dissolve, liquidate, reorganize or restructure; merge with any other entity; commence any case, proceeding or other action under bankruptcy, insolvency or similar law; acquire or dispose of assets other than in the ordinary course of business. Also, the Company shall not, without prior written consent of holder of the KKR Notes, approve any budget or business plan or incur any indebtedness such that the outstanding indebtedness is in excess of US$22,000. Any amendment or waiver thereof requires the affirmative consent of a majority of the holder of all outstanding Notes. Additionally, additional payments on the Notes shall be made in the event the Group pays any excess cash dividend in any financial year (see Note 19). Such term provides the holders of the KKR Notes and GM Notes with the ability to participate in any excess cash dividend.

The Company has determined that the conversion feature embedded in the Notes should not be bifurcated and accounted for as a derivative pursuant to ASC 815, Derivatives and Hedging, since the embedded conversion feature is indexed to the Company’s own stock and would have been classified in shareholders’ equity if it were a free-standing derivative instrument. The Company has determined that the embedded put options that can accelerate the repayment of the Notes and contingent interest feature are clearly and closely related to the debt host contract and are not separately accounted for as a derivative pursuant to the ASC 815. Further, since the conversion price of the Notes exceeded the market price of the Company’s ordinary shares on the date of commitment, there was no beneficial conversion feature.

The Company accrued interest on the Notes based on the guaranteed 12% IRR per annum. The difference between the accrued interest rate of 12% and the coupon rate of 7% of the Notes is recorded in convertible notes in the consolidated balance sheets. Debt issuance costs capitalized in connection with the issuance of convertible notes are amortized from the date the Notes were issued to the earliest date the holders of the Notes can demand payment, which is five years.

Interest relating to the Notes was recognized as follows:

	Year ended March 31,
	2013		2014		2015	2015
	RMB		RMB		RMB	US$

KKR Notes interest incurred	45,959		50,475		53,222	8,586
GM Notes interest incurred	18,761		37,994		40,008	6,454
Amortization of debt issuance costs	3,062		3,610		3,610	582
Interest cost capitalized	(1,207	)	(24,822	)	—	—

Total interest expense	66,575		67,257		96,840	15,622

Shareholders' equity	12 Months Ended
Shareholders' equity	Mar. 31, 2015
Shareholders' equity
Shareholders' equity	15Shareholders’ equity (a)Share capital The Company had 73,140,147 shares outstanding as of March 31, 2012. During the year ended March 31, 2013, 7,450,914 ordinary shares were repurchased under the share repurchase program (see Note 15(c)), and 7,314,015 of them were sold to CGL (see Note 1(b)). The remaining 136,899 ordinary share repurchased had not been cancelled and was presented as treasury stock in the consolidated balance sheets. As a result, the Company had 73,003,248 shares outstanding as of March 31, 2013, 2014 and 2015. (b)Statutory reserves According to PRC rules and regulations and their Articles of Association, Beijing Jiachenhong, Guangzhou Nuoya and Zhejiang Lukou are required to transfer 10% of net income, as determined in accordance with the relevant financial regulations established by the Ministry of Finance of the PRC, to a statutory surplus reserve until the reserve balance reaches 50% of their respective registered capital. The transfer to this reserve must be made before distribution of dividends to equity holders can be made. The statutory surplus reserve is non-distributable but can be used to make good previous years’ losses, if any, and may be converted into issued capital in proportion to the respective equity holding of the equity holders, provided that the balance of the reserve after such conversion is not less than 25% of the registered capital. Transfers of RMB22,638, RMB22,858 and RMB8,471 (US$1,367) have been made to the statutory surplus reserve by Beijing Jiachenhong, Guangzhou Nuoya and Zhejiang Lukou for the years ended March 31, 2013, 2014 and 2015, respectively. Accumulated statutory surplus reserve as of March 31, 2014 and 2015 amounted to RMB100,937 and RMB109,408 (US$17,649), respectively. (c)Share repurchase program On September 15, 2010, the Group announced the authorization of a share repurchase program under which the Company was entitled to repurchase up to US$15,000 of its outstanding ordinary shares. Pursuant to this program, the Company was entitled to repurchase its shares for a period of one year commencing on September 15, 2010 in the open market at prevailing market prices or in block trades. On August 3, 2011, the Board of Directors approved the refreshment of the program for 12 months until August 2, 2012. On July 31, 2012, the Board of Directors approved a new US$20,000 share repurchase program to replace the previous US$15,000 share repurchase program that expired. During the year ended March 31, 2013, the Company repurchased 7,450,914 ordinary shares at a total cost of RMB131,302 of which 7,314,015 shares were subsequently sold to CGL (Note 1(b)). The remaining 136,899 repurchased ordinary shares had not been cancelled and therefore were presented as treasury stock in the consolidated balance sheets. On July 24, 2013, July 30, 2014 and July 30, 2015, the Board of Directors approved a new share repurchase program in the aggregate amount of $20,000 for 12 months until July 24, 2014, July 30, 2015 and July 30, 2016, respectively. During the years ended March 31, 2014 and 2015, the Company did not repurchase any of its shares under the new share repurchase programs.

Revenues

12 Months Ended

Mar. 31, 2015

Revenues

Revenues

16Revenues

The Group’s revenues are primarily derived from the provision of umbilical cord blood processing and storage services.

In view of the fact that the Group operates and manages its business solely in the PRC and services are predominately provided to customers located in the PRC, no geographical segment information is provided.

The Group’s revenues by category are as follows:

	Year ended March 31,
	2013	2014	2015	2015
	RMB	RMB	RMB	US$

Cord blood processing fees	394,641	403,058	428,261	69,086
Cord blood storage fees	129,455	166,649	203,847	32,884
Fees derived from the provision of donated cord blood for transplantation and research and others	2,027	3,150	3,014	486

Total revenues	526,123	572,857	635,122	102,456

Income tax

12 Months Ended

Mar. 31, 2015

Income tax

Income tax

17Income tax

Cayman Islands and British Virgin Islands

Under the current laws of the Cayman Islands and the British Virgin Islands, the Company and its subsidiaries that are incorporated in the Cayman Islands and the British Virgin Islands are not subject to tax on income or capital gains. In addition, upon payments of dividends by these companies, no Cayman Islands or British Virgin Islands withholding tax is imposed.

Hong Kong

The Company’s subsidiaries that are incorporated or operate in Hong Kong are subject to Hong Kong Profits Tax on income arising in or derived from Hong Kong. No provision was made for Hong Kong Profits Tax as the subsidiaries did not earn income subject to Hong Kong Profits Tax for the years ended March 31, 2013, 2014 and 2015. The payments of dividends by Hong Kong tax residents are not subject to any Hong Kong withholding tax.

The PRC

The Company’s PRC subsidiaries are subject to PRC statutory income tax rate of 25% unless otherwise specified.

In February 2012, Beijing Jiachenhong received approval from the tax authority on the renewal of its High and New Technology Enterprises (“HNTE”) status which entitled it to the preferential income tax rate of 15% effective retroactively from January 1, 2011 to December 31, 2013. In January 2015, Beijing Jiachenhong received approval from the tax authority on the renewal of its HNTE status which entitled it to the preferential income tax rate of 15% effective retroactively from January 1, 2014 to December 31, 2016.

In June 2011, Guangzhou Nuoya received approval from the tax authority that it qualified as a HNTE which entitled it to the preferential income tax rate of 15% effective retrospectively from January 1, 2010 to December 31, 2012. In April 2014, Guangzhou Nuoya received approval from the tax authority on the renewal of its HNTE status which entitled it to the preferential income tax rate of 15% effective retroactively from January 1, 2013 to December 31, 2015.

The Enterprise Income Tax Law and its implementation rules also impose a withholding tax at 10%, unless reduced by a tax treaty or agreement, for dividends receivable by non-PRC-resident enterprises from PRC-resident enterprises in respect of earnings accumulated beginning on January 1, 2008. During the year ended March 31, 2014, withholding tax of RMB6,000 was levied on dividends distributed by the Company’s PRC subsidiary to the holding company outside the PRC. As of March 31, 2014 and 2015, the Company has provided RMB3,900 and RMB9,100 (US$1,468) for withholding income tax on a portion of the undistributed earnings of its PRC subsidiaries according to management’s reinvestment plan. No income taxes were provided for the remaining undistributed earnings which are intended to be reinvested indefinitely in the PRC. As of March 31, 2015, such unremitted earnings that may be subject to the withholding tax amounted to RMB953,111 (US$153,752) and the related unrecognized deferred tax liability was RMB95,311 (US$15,375).

Income before income tax expense arose from the following tax jurisdictions:

	Year ended March 31,
	2013		2014		2015		2015
	RMB		RMB		RMB		US$

The PRC	260,462		316,933		284,288		45,860
Non-PRC	(102,277	)	(126,009	)	(129,168	)	(20,836	)

Income before income tax expense	158,185		190,924		155,120		25,024

(a)Income taxes

Income tax expense represents PRC income tax expense as follows:

	Year ended March 31,
	2013		2014	2015		2015
	RMB		RMB	RMB		US$

Current tax expense	38,737		50,000	48,239		7,782
Deferred tax benefit	(194	)	8,398	(912	)	(147	)
Total income tax expense	38,543		58,398	47,327		7,635

(b)Reconciliation of expected income tax to actual income tax expense

The actual income tax expense reported in the consolidated statements of comprehensive income differs from the amount computed by applying the statutory PRC income tax rate of 25% for the following reasons:

	Year ended March 31,
	2013		2014		2015		2015
	RMB		RMB		RMB		US$

Income before income tax expense	158,185		190,924		155,120		25,024


Computed “expected” tax expense	39,546		47,731		38,780		6,256
Non-PRC entities not subject to income tax	25,569		31,502		32,292		5,209
PRC dividend withholding tax	—		9,887		5,200		839
Non-taxable income	—		(1,874	)	—		—
Tax rate differential, preferential tax	(26,015	)	(29,011	)	(29,663	)	(4,785	)
Others	(557	)	163		718		116

Actual income tax expense	38,543		58,398		47,327		7,635

(c)Deferred taxes

The tax effects of temporary differences that give rise to deferred tax assets/(liabilities) are presented below:

	March 31,
	2014		2015		2015
	RMB		RMB		US$
Deferred tax assets:
Accounts receivable	6,812		9,975		1,609
Non-current accounts receivable	6,406		8,871		1,431
Inventories	2,293		2,278		367
Others	1,226		678		109

Net deferred tax assets	16,737		21,802		3,516


Deferred tax liabilities:
Deferred revenue	(96	)	(86	)	(14	)
Property, plant and equipment	(4,988	)	(5,107	)	(823	)
PRC dividend withholding tax	(3,900	)	(9,100	)	(1,468	)
Intangible assets	(30,138	)	(28,982	)	(4,675	)

Deferred tax liabilities	(39,122	)	(43,275	)	(6,980	)


Net deferred tax liabilities	(22,385	)	(21,473	)	(3,464	)


Classification on consolidated balance sheets:
Current deferred tax assets	7,664		10,270		1,657
Current deferred tax liabilities	(3,900	)	(9,100	)	(1,468	)
Non-current deferred tax assets	1,789		2,618		422
Non-current deferred tax liabilities	(27,938	)	(25,261	)	(4,075	)

Net deferred tax liabilities	(22,385	)	(21,473	)	(3,464	)

For the years ended March 31, 2013, 2014 and 2015, the Group did not have any material unrecognized tax benefits and thus no interest and penalties related to unrecognized tax benefits were recorded. In addition, the Company does not expect that the amount of unrecognized tax benefits will change significantly within the next twelve months.

According to the PRC Tax Administration and Collection Law, the statute of limitation is three years if the underpayment of taxes is due to computational errors made by the taxpayer or the withholding agent. The statute of limitation is extended to five years under special circumstances where the underpayment of taxes is more than RMB100 (US$16). In the case of transfer pricing issues, the statute of limitation is ten years. There is no statute of limitation in the case of tax evasion. The income tax returns of the Group’s PRC subsidiaries for the calendar years from 2010 to 2014 are open to examination by the PRC state and local tax authorities.

Share-based compensation

12 Months Ended

Mar. 31, 2015

Share-based compensation.

Share-based compensation

18Share-based compensation

At the annual general meeting of the Company on February 18, 2011 (the “Adoption Date”), the shareholders of the Company approved a restricted share unit (the “RSU Scheme”) for the purpose of attracting and retaining skilled and experienced personnel. Certain administrative provisions of the RSU scheme were subsequently amended by the Board of Directors of the Company in August 2014. The RSU Scheme will be valid and effective for a period of ten years commencing from the Adoption Date of the RSU Scheme.

On December 15, 2014 (the “Grant Date”), the Company granted a total of 7,300,000 restricted share units (“RSUs”) to certain executives, directors and key employees (the “RSU Grantees”) under the RSU Scheme. The RSUs will be vested in whole at any time during its valid period, subject to the fulfilment of certain operational and/or financial performance targets as set by relevant committee of the Company’s Board of Directors from time to time. Upon vesting, each RSU shall be entitled to the transfer or issue of one ordinary share in the share capital of the Company. The RSUs are exercisable only if the RSU Grantees remained employed by the Company.

On December 15, 2014, the Company established a trust (the “Trust”) to facilitate the operation of the RSU Scheme and to hold ordinary shares for the benefit of the RSU Grantees as a class. The Trust is administered by a trustee (the “Trustee”) pursuant to the deed of settlement entered into between the Company and the Trustee. On the same day, out of 7,300,000 RSUs granted, 7,080,000 ordinary shares were issued by the Company and deposited into the Trust. Such ordinary shares will be transferred to respective RSU Grantees (or their designated nominees) when the vesting conditions are fulfilled and upon the confirmation of the Board of Directors of the Company. The total equity investment of the Trustee is not sufficient to permit itself to finance its activities without additional subordinated financial support by other parties (e.g. the Company). Also, the Trustee is enslaved to the deed of settlement to manage the Trust fund upon the instructions from the Company. Thus, equity holder of the Trustee does not have the direct or indirect ability to make decisions about the Trustee’s activities that have a significant effect on the success of the Trustee through its equity interest.

The fair value of each RSU is US$4.15, which was based on the market price of the ordinary shares of the Company at Grant Date. During the year ended March 31, 2015, the RSUs granted had not been vested and there were 7,300,000 RSUs outstanding and nil exercisable as of March 31, 2015 with a weighted average remaining contract life of 3 years. Management assessed that the satisfaction of the operational and/or financial performance targets of the RSUs granted are achievable within its valid period.

Share-based compensation expense recognized for non-vested RSUs is allocated to the following expense items:

	Year ended March 31,
	2013	2014	2015	2015
	RMB	RMB	RMB	US$

Direct costs	—	—	416	67
Sales and marketing	—	—	4,624	746
General and administrative	—	—	11,495	1,854

Total share-based compensation expense	—	—	16,535	2,667

Net income per share

12 Months Ended

Mar. 31, 2015

Net income per share

Net income per share

19Net income per share

The following table sets forth the computation of basic net income per share and diluted net income per share for the years ended March 31, 2013, 2014 and 2015:

	Year ended March 31,
	Note	2013		2014		2015		2015
		RMB		RMB		RMB		US$
Numerator:
Net income attributable to the Company’s shareholders		112,447		131,903		107,292		17,308
Earnings allocated to participating convertible notes	(i)	(6,053	)	(15,050	)	(8,108	)	(1,308	)


Net income for basic and diluted net income per share		106,394		116,853		99,184		16,000


Denominator:
Weighted average ordinary shares outstanding for basic and diluted net income per share		71,527,698		73,003,248		73,003,248		73,003,248


Net income per share attributable to ordinary shares:
- Basic		1.49		1.60		1.36		0.22

- Diluted	(ii)	1.49		1.60		1.36		0.22

Notes:

(i)

The outstanding convertible notes provide the holders with the ability to participate in any excess cash dividend. Excess cash dividend means any cash dividend to holders of shares that, together with all other cash dividends previously paid to holders of shares in the same financial year, exceeds, on a per share basis, an amount equal to the interest that has accrued and shall accrue at 7% coupon interest rate in such financial year divided by the number of shares into which the notes are convertible at the conversion price then in effect on the relevant record date. Therefore, net income attributable to the Company is reduced by such allocated earnings to participating convertible notes for the years ended March 31, 2013, 2014 and 2015 in both basic and diluted net income per share computation.

(ii)

During the years ended March 31, 2013, 2014 and 2015, the Company had potentially dilutive ordinary shares of 40,521,495 representing shares issuable upon conversion of the outstanding convertible notes (see Note 14). Such potentially dilutive ordinary shares were excluded from diluted net income per share computation because their effects would have been anti-dilutive.

Related party transactions

12 Months Ended

Mar. 31, 2015

Related party transactions

Related party transactions

20Related party transactions

For the years presented, the principal related party transactions and amounts due to related parties are summarized as follows:

		Year ended March 31,
	Note	2013	2014	2015	2015
		RMB	RMB	RMB	US$

Rental of properties	(i)	1,440	1,440	1,440	232
Raw material purchase	(ii)	—	14,336	15,683	2,530
Consultancy expenses	(iii)	—	904	1,984	320
Interest expenses	14	18,761	37,994	40,008	6,454
License fee	(iv)	—	—	321	52

		March 31,
	Note	2014	2015	2015
		RMB	RMB	US$

Current liabilities:
Amounts due to related parties	(i), (ii) & 14	21,453	20,802	3,355

Note:

(i)

During the years ended March 31, 2013, 2014 and 2015, Beijing Jingjing Medical Equipment Co., Ltd. (“Beijing Jingjing”), a subsidiary of GMHL, leased a property to the Group under an operating lease. The monthly rental was RMB174 and renewed at a monthly rental of RMB120 effective from July 2009. The lease period was 5.5 years and expired in December 2014. In December 2014, the lease was further renewed at a monthly rental of RMB120 (US$19) for a period of 5 years expiring in December 2019 and does not include contingent rentals.

(ii)

During the years ended March 31, 2014 and 2015, the Group purchased raw materials from China Bright Group Co. Limited, a subsidiary of GMHL, for an amount of RMB14,336 and RMB15,683 (US$2,530), respectively.

(iii)

During the years ended March 31, 2014 and 2015, consultancy services were provided by Golden Meditech (S) Pte Ltd., a subsidiary of GMHL, to the Group for an amount of RMB904 and RMB1,984 (US$320), respectively.

(iv)

During the year ended March 31, 2015, CGL charged a license fee payable to the Group for an amount of RMB321 (US$52).

Pension and other postretirement benefits	12 Months Ended
Pension and other postretirement benefits	Mar. 31, 2015
Pension and other postretirement benefits
Pension and other postretirement benefits	21Pension and other postretirement benefits Pursuant to the relevant PRC regulations, Beijing Jiachenhong, Guangzhou Nuoya and Zhejiang Lukou are required to make contributions for each employee at a rate of approximately 20% on a standard salary base as determined by the local Social Security Bureau, to a defined contribution retirement scheme organized by the local Social Security Bureau. The amounts of contributions of RMB12,158, RMB14,337 and RMB17,018 (US$2,745) for the years ended March 31, 2013, 2014 and 2015 respectively, were charged to expense in the consolidated statements of comprehensive income. The Group has no other obligation to make payments in respect of retirement benefits of the employees.

Fair value measurements	12 Months Ended
Fair value measurements	Mar. 31, 2015
Fair value measurements
Fair value measurements	22Fair value measurements The following methods and assumptions were used to estimate the fair value of each class of financial instruments: Trading securities and available-for-sale equity securities — based on quoted market prices on the last trading value as of March 31, 2015. Such investments are classified as Level 1 in the hierarchy. Short-term financial instruments (including cash and cash equivalents, accounts receivable, accounts payable, accrued expenses, other receivables/payables, amounts due to related parties, and short-term bank loan) — cost approximates their respective fair values due to their short-term nature. Convertible notes — the estimated fair value was US$176,640 and US$218,666 (RMB1,355,511) as of March 31, 2014 and 2015 based on the level 3 valuation technique as compared to a carrying value of RMB777,753 and RMB815,851 (US$131,610) as of March 31, 2014 and 2015. The estimated fair value of the convertible notes is based on a mark-to-model valuation model. Due to the fact that there is no active market for this instrument, the fair value of the convertible notes was estimated using a discounted cash flow analysis based on current borrowing rates for instruments with similar terms. In addition, the Company utilized other sources of information for the relevant market parameters in order to develop its fair value.

Business and credit concentrations

12 Months Ended

Mar. 31, 2015

Business and credit concentrations

Business and credit concentrations

23Business and credit concentrations

All of the Group’s customers are located in the PRC. Revenues from and gross accounts receivable due from customers are individually immaterial.

The Group purchases raw materials from a few major suppliers. The following are purchases from suppliers that individually comprise 10% or more of gross purchases in the respective years:

	Year ended March 31,
Suppliers	2013		2014		2015
	RMB	%	RMB	%	RMB	US$	%

China Bright Group Co. Limited	—	—	14,336	23	15,683	2,530	25
Hangzhou Baitong Biological Technology Co., Ltd.	7,783	15	—	—	6,600	1,065	10
Shanghai Qiangzhi Biological Technology Co., Ltd.	11,152	22	7,195	11	—	—	—
Cesca Therapeutics Inc.	—	—	10,841	17	—	—	—

Total	18,935	37	32,372	51	22,283	3,595	35

As of March 31, 2014 and 2015, there was no individual accounts payable due to major suppliers that exceeded 10% of outstanding accounts payable balance.

Commitments and contingencies

12 Months Ended

Mar. 31, 2015

Commitments and contingencies

Commitments and contingencies

24Commitments and contingencies

(a)Operating lease commitments

For the years ended March 31, 2013, 2014 and 2015, total rental expenses for operating leases were RMB4,666, RMB3,735 and RMB4,536 (US$732), respectively.

The total future minimum payments under non-cancellable operating leases of rental arrangements as of March 31, 2015 are as follows:

	March 31, 2015
	RMB	US$
Fiscal years ending March 31,
2016	1,799	290
2017	1,668	270
2018	1,596	257
2019	1,596	257
2020	1,106	178

Total payments	7,765	1,252

(b)Contractual commitments

The Group entered into an agreement with an institution for the research and development of medicines for treatments which make use of cord blood stem cells. Commitments as of March 31, 2014 and 2015 under this agreement amounted to RMB2,000 (US$323), respectively.

In June 2006, the Group entered into a cooperation agreement with Peking University People’s Hospital (“PUPH”). Pursuant to the agreement, PUPH provides technical consultancy services to the Group in relation to the operation of a cord blood bank. The yearly service fee was RMB2,000 and was renewed at a yearly service fee of RMB2,600 (US$419) effective from October 2013. The renewed agreement has a term of twenty years commencing in October 2013.

In November 2009, Guangzhou Nuoya entered into a cooperation agreement with Guangdong Women and Children’s Hospital and Health Institute (“GWCH”). Pursuant to the agreement, GWCH provides technical consultancy services to the Group. The yearly service fee was RMB2,000 and was renewed at a yearly service fee of RMB3,200 (US$516) effective from October 2013.

As of March 31, 2015, the total future minimum payments under the cooperation agreements are as follows:

	March 31, 2015
	RMB	US$
Fiscal years ending March 31,
2016	5,800	936
2017	5,800	936
2018	5,800	936
2019	5,800	936
2020	5,800	936
2021 and thereafter	65,767	10,608

Total payments	94,767	15,288

Subsequent events	12 Months Ended
Subsequent events	Mar. 31, 2015
Subsequent events
Subsequent events	25Subsequent events On April 27, 2015, the Company’s Board of Directors received a non-binding proposal letter from GMHL, pursuant to which GMHL proposes to acquire all of the outstanding ordinary shares of the Company not already directly or indirectly owned by GMHL for US$6.40 per ordinary share in cash (the “GMHL Proposal”). According to the proposal letter, the proposed transaction is intended to be financed with a combination of available cash resources of GMHL and debt and equity capital. In connection with the proposed transaction, GMHL intends to acquire all of the Company’s outstanding 7% senior unsecured convertible notes held by KKRCHIL, Magnum and CGL, as well as ordinary shares of the Company held by CGL, pursuant to the terms and conditions of respective purchase agreement. On April 29, 2015, the Company announced that in response to the non-binding proposal letter received from GMHL, the Board of Directors has formed a special committee of independent directors who are not affiliated with GMHL (the “Special Committee”) to evaluate and consider the GMHL Proposal and certain other potential transactions involving the Company. Since being formed, the Special Committee has engaged legal and financial advisors but has not set a definitive timetable to complete its evaluation of the GMHL Proposal or any other alternatives. As of the date of this report, the Special Committee is still considering and evaluating the proposal by GMHL, but it has not made any decision regarding the GMHL Proposal.

Summary of significant accounting policies (Policy)

12 Months Ended

Mar. 31, 2015

Summary of significant accounting policies

Principles of consolidation

(a)Principles of consolidation

Use of estimates

(b)Use of estimates

Foreign currency transactions and translation

(c)Foreign currency transactions and translation

The reporting currency of the Company is Renminbi (“RMB”).

Cash and cash equivalents

(d)Cash and cash equivalents

	March 31,
	2014		2015
	Foreign currency	RMB	Foreign currency	RMB

U.S. dollars	398	2,474	28,168	173,419
Australian dollars	242	1,378	1	5
Renminbi	1,812,025	1,812,025	2,261,327	2,261,327
Hong Kong dollars	81,188	64,503	2,361	1,863
Singapore dollars	515	2,521	9	41

Investment securities

(e)Investment securities

Management determines the appropriate classification of its investment securities at the time of purchase and reevaluates such designations at each reporting date.

Trading securities are recorded at fair value. Unrealized holding gains and losses, net of the related tax effect, on trading securities are included in earnings.

Dividend income is recognized in other income when earned.

Accounts receivable

(f)Accounts receivable

Inventories

(g)Inventories

Property, plant and equipment

(h)Property, plant and equipment

Property, plant and equipment are stated at cost less accumulated depreciation.

Buildings		37.5 — 50 years
Leasehold improvements		Shorter of the lease term or estimated useful lives of 10 years
Machineries		5 — 10 years
Motor vehicles		5 years
Furniture, fixtures and office equipment		3 — 5 years

No depreciation expense is provided in respect of construction-in-progress.

Intangible assets

(i)Intangible assets

Impairment of long-lived assets

(j)Impairment of long-lived assets

Revenue recognition

(k)Revenue recognition

Pursuant to the Agreement, no penalty is charged to customers for early termination of the cord blood storage service.

The Group considers all reasonably available information to allocate the overall arrangement fee to cord blood processing and cord blood storage services based on their relative selling prices.

During the years ended March 31, 2013, 2014 and 2015, the Group offered its customers three payment options:

(i)Payment of the processing fee upon delivery of the cord blood unit to the Group’s premises for processing and the annual storage fee in advance at the beginning of each one-year renewal period;

(ii)Payment of the processing fee upon delivery of the cord blood unit to the Group’s premises for processing and an upfront payment of storage fees for a period of eighteen years; and

Research and development costs

(l)Research and development costs

Advertising and promotion costs

(m)Advertising and promotion costs

Retirement and other postretirement benefits

(n)Retirement and other postretirement benefits

Debt issuance costs

(o)Debt issuance costs

Income taxes

(p)Income taxes

Commitments and contingencies

(q)Commitments and contingencies

Earnings per share

(r)Earnings per share

Share-based compensation

(s)Share-based compensation

Segment reporting

(t)Segment reporting

Fair value measurement

(u)Fair value measurement

Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.

See Note 22 to the consolidated financial statements.

Recently issued accounting standards

(v)Recently issued accounting standards

Summary of significant accounting policies (Tables)

12 Months Ended

Mar. 31, 2015

Summary of significant accounting policies

Schedule of Cash and Cash Equivalents Denominated in Currencies

	March 31,
	2014		2015
	Foreign currency	RMB	Foreign currency	RMB

U.S. dollars	398	2,474	28,168	173,419
Australian dollars	242	1,378	1	5
Renminbi	1,812,025	1,812,025	2,261,327	2,261,327
Hong Kong dollars	81,188	64,503	2,361	1,863
Singapore dollars	515	2,521	9	41

Schedule of Depreciation Policy of Property, Plant and Equipment

Buildings		37.5 — 50 years
Leasehold improvements		Shorter of the lease term or estimated useful lives of 10 years
Machineries		5 — 10 years
Motor vehicles		5 years
Furniture, fixtures and office equipment		3 — 5 years

Accounts receivable, net (Tables)

12 Months Ended

Mar. 31, 2015

Accounts receivable, net

Schedule of Accounts Receivable

	March 31,
	2014		2015		2015
	RMB		RMB		US$

Accounts receivable	383,794		398,835		64,338
Less: Allowance for doubtful accounts	(63,025	)	(83,835	)	(13,524	)

Total accounts receivable, net	320,769		315,000		50,814


Representing:

Current portion:
- Processing fees	64,838		78,911		12,729
- Storage fees	28,894		39,522		6,375
- Others	1,541		2,329		376

	95,273		120,762		19,480
Non-current portion:
- Processing fees	225,496		194,238		31,334

Total accounts receivable, net	320,769		315,000		50,814

Schedule of Non-Current Gross Accounts Receivable Due for Payment

	March 31, 2015
	RMB	US$
Fiscal years ending March 31,
2017	31,504	5,082
2018	30,874	4,980
2019	29,133	4,700
2020	29,558	4,768
2021 and thereafter	184,118	29,701

	305,187	49,231

Schedule of Allowance for Doubtful Accounts

	Year ended March 31,
	2013		2014		2015		2015
	RMB		RMB		RMB		US$

Balance at beginning of year	52,544		50,473		63,025		10,167
Charged to allowance for doubtful accounts	7,468		17,973		25,042		4,040
Write-off charged against the allowance for the year	(9,539	)	(5,421	)	(4,232	)	(683	)

Balance at end of year	50,473		63,025		83,835		13,524

Inventories (Tables)

12 Months Ended

Mar. 31, 2015

Inventories

Schedule of Inventories

	March 31,
	2014	2015	2015
	RMB	RMB	US$

Current portion:
- Consumables and supplies	31,583	23,803	3,840

Non-current portion:
- Processing costs capitalized in donated umbilical cord blood	48,385	58,224	9,392


Total current and non-current inventories	79,968	82,027	13,232

Prepaid expenses and other receivables (Tables)

12 Months Ended

Mar. 31, 2015

Prepaid expenses and other receivables

Schedule of Prepaid Expenses and Other Receivables

	March 31,
	2014	2015	2015
	RMB	RMB	US$

Prepaid expenses	20,593	14,326	2,311
Tax receivables	13,406	548	88
Other receivables	3,011	4,634	748

Total prepaid expenses and other receivables	37,010	19,508	3,147

Property, plant and equipment, net (Tables)

12 Months Ended

Mar. 31, 2015

Property, plant and equipment, net

Schedule of Property, Plant and Equipment, Net

	March 31,
	2014		2015		2015
	RMB		RMB		US$

Buildings	578,513		581,252		93,766
Leasehold improvements	14,864		14,864		2,398
Machineries	118,449		137,811		22,231
Motor vehicles	14,885		15,209		2,453
Furniture, fixtures and equipment	35,433		40,132		6,474
Construction-in-progress	9,684		4,283		691

	771,828		793,551		128,013
Less: Accumulated depreciation	(145,196	)	(190,384	)	(30,712	)

Total property, plant and equipment, net	626,632		603,167		97,301

Schedule of Depreciation Expense of Property, Plant and Equipment


	Year ended March 31,
	2013	2014	2015	2015
	RMB	RMB	RMB	US$

Direct costs	17,421	18,150	28,819	4,649
Research and development	2,073	1,863	2,231	360
Sales and marketing	2,805	2,611	2,530	408
General and administrative	8,954	9,820	12,408	2,002

Total depreciation expense	31,253	32,444	45,988	7,419

Schedule of interest cost incurred



	Year ended March 31,
	2013	2014	2015	2015
	RMB	RMB	RMB	US$

Interest cost capitalized	1,274	25,912	—	—
Interest cost charged to income	70,097	70,075	101,102	16,309

Total interest cost incurred	71,371	95,987	101,102	16,309

Non-current deposits (Tables)

12 Months Ended

Mar. 31, 2015

Non-current deposits

Schedule of Non-Current Deposits

		March 31,
	Note	2014	2015	2015
		RMB	RMB	US$

Investment deposit	(i)	208,591	207,226	33,429
Deposit for machineries purchase		303	32	5

Total non-current deposits		208,894	207,258	33,434

Note:

(i)

Intangible assets, net (Tables)

12 Months Ended

Mar. 31, 2015

Intangible assets, net

Schedule of Components of Intangible Assets, Net

	March 31,
	2014		2015		2015
	RMB		RMB		US$

Cord blood bank operating rights	138,628		138,628		22,363
Less: Accumulated depreciation	(18,079	)	(22,700	)	(3,662	)

Total intangible assets, net	120,549		115,928		18,701

Schedule of Estimated Amortization Expenses

	March 31, 2015
	RMB	US$
Fiscal years ending March 31,
2016	4,621	745
2017	4,621	745
2018	4,621	745
2019	4,621	745
2020 and thereafter	97,444	15,721

Total amortization expenses	115,928	18,701

Available-for-sale equity securities (Tables)

12 Months Ended

Mar. 31, 2015

Available-for-sale equity securities

Schedule of Available-for-Sale Equity Securities

	March 31,
	2014	2015	2015
	RMB	RMB	US$

Life Corporation Limited - listed on Australian Securities Exchange	4,630	4,205	678
Cordlife Group Limited - listed on Singapore Exchange	139,617	118,211	19,070

Total listed equity securities, at market	144,247	122,416	19,748

Other investment (Tables)

12 Months Ended

Mar. 31, 2015

Other investment

Schedule of Other Investment

	March 31,
	2014	2015	2015
	RMB	RMB	US$

Unlisted equity securities, at cost	189,129	189,129	30,510

Accrued expenses and other payables (Tables)

12 Months Ended

Mar. 31, 2015

Accrued expenses and other payables

Schedule of Accrued Expenses and Other Payables

		March 31,
	Note	2014	2015	2015
		RMB	RMB	US$

Insurance premium received on behalf of insurance company	(i)	15,292	20,035	3,233
Other tax payables		3,927	3,312	534
Accrued salaries, bonus and welfare expenses		23,005	21,026	3,392
Accrued consultancy and professional fees		3,599	3,287	530
Accrued interest on convertible notes	(ii)	26,188	26,017	4,197
Payable for property, plant and equipment		15,969	694	112
Other payables	(iii)	14,579	13,010	2,099

Total accrued expenses and other payables		102,559	87,381	14,097

Notes:

(i)	The Group has an agreement with an insurance company under which the Group is granted the authority to collect insurance premiums on behalf of the insurance company from customers who store umbilical cord blood in the Group’s cord blood bank and are enrolled in the insurance scheme offered by the insurance company. The insurance premiums amount collected and payable over one year are recorded in other non-current liabilities in the consolidated balance sheets.

(ii)	Accrued interest on convertible notes represents the interest accrued based on coupon interest rate of 7% of outstanding principle of convertible notes, which is to be settled annually on April 27 (Note 14).

(iii)	Other payables mainly include fee refundable to customers whose cord blood unit does not qualify for subsequent storage and other operating procurement payables.

Deferred revenue (Tables)

12 Months Ended

Mar. 31, 2015

Deferred revenue

Schedule of Deferred Revenue

	March 31,
	2014	2015	2015
	RMB	RMB	US$

Payments by customers prior to completion of cord blood processing services	93,597	87,296	14,082
Unearned storage fees	926,756	1,232,243	198,781

Total current and non-current deferred revenue	1,020,353	1,319,539	212,863


Representing:
Current portion	196,432	220,140	35,512
Non-current portion	823,921	1,099,399	177,351

Total current and non-current deferred revenue	1,020,353	1,319,539	212,863

Schedule of Unearned Storage Fees

	Year ended March 31,
	2013		2014		2015		2015
	RMB		RMB		RMB		US$

Balance at beginning of year	361,034		608,115		926,756		149,501
Deferred revenue arising from new customers	376,536		485,290		509,334		82,164
Credited to income	(129,455	)	(166,649	)	(203,847	)	(32,884	)

Balance at end of year	608,115		926,756		1,232,243		198,781

Convertible notes (Tables)

12 Months Ended

Mar. 31, 2015

Convertible notes

Schedule of Convertible Notes

	March 31,
	2014	2015	2015
	RMB	RMB	US$

Principal amount of the KKR Notes	403,315	400,175	64,554
Principal amount of the GM Notes	310,302	307,828	49,658
Cumulative interest payables	64,136	107,848	17,398

Carrying amount	777,753	815,851	131,610

Schedule of Interest Relating to KKR Notes and GM Notes

	Year ended March 31,
	2013		2014		2015	2015
	RMB		RMB		RMB	US$

KKR Notes interest incurred	45,959		50,475		53,222	8,586
GM Notes interest incurred	18,761		37,994		40,008	6,454
Amortization of debt issuance costs	3,062		3,610		3,610	582
Interest cost capitalized	(1,207	)	(24,822	)	—	—

Total interest expense	66,575		67,257		96,840	15,622

Revenues (Tables)

12 Months Ended

Mar. 31, 2015

Revenues

Schedule of Revenue from External Customers

	Year ended March 31,
	2013	2014	2015	2015
	RMB	RMB	RMB	US$

Cord blood processing fees	394,641	403,058	428,261	69,086
Cord blood storage fees	129,455	166,649	203,847	32,884
Fees derived from the provision of donated cord blood for transplantation and research and others	2,027	3,150	3,014	486

Total revenues	526,123	572,857	635,122	102,456

Income tax (Tables)

12 Months Ended

Mar. 31, 2015

Income tax

Schedule of Income before Income Tax Expense

	Year ended March 31,
	2013		2014		2015		2015
	RMB		RMB		RMB		US$

The PRC	260,462		316,933		284,288		45,860
Non-PRC	(102,277	)	(126,009	)	(129,168	)	(20,836	)

Income before income tax expense	158,185		190,924		155,120		25,024

Schedule of Income Tax (Benefit) Expense

	Year ended March 31,
	2013		2014	2015		2015
	RMB		RMB	RMB		US$

Current tax expense	38,737		50,000	48,239		7,782
Deferred tax benefit	(194	)	8,398	(912	)	(147	)
Total income tax expense	38,543		58,398	47,327		7,635

Schedule of the Reconciliation between the Statutory rate and the Effective tax rate

	Year ended March 31,
	2013		2014		2015		2015
	RMB		RMB		RMB		US$

Income before income tax expense	158,185		190,924		155,120		25,024


Computed “expected” tax expense	39,546		47,731		38,780		6,256
Non-PRC entities not subject to income tax	25,569		31,502		32,292		5,209
PRC dividend withholding tax	—		9,887		5,200		839
Non-taxable income	—		(1,874	)	—		—
Tax rate differential, preferential tax	(26,015	)	(29,011	)	(29,663	)	(4,785	)
Others	(557	)	163		718		116

Actual income tax expense	38,543		58,398		47,327		7,635

Schedule of Deferred Tax Assets and Liabilities

	March 31,
	2014		2015		2015
	RMB		RMB		US$
Deferred tax assets:
Accounts receivable	6,812		9,975		1,609
Non-current accounts receivable	6,406		8,871		1,431
Inventories	2,293		2,278		367
Others	1,226		678		109

Net deferred tax assets	16,737		21,802		3,516


Deferred tax liabilities:
Deferred revenue	(96	)	(86	)	(14	)
Property, plant and equipment	(4,988	)	(5,107	)	(823	)
PRC dividend withholding tax	(3,900	)	(9,100	)	(1,468	)
Intangible assets	(30,138	)	(28,982	)	(4,675	)

Deferred tax liabilities	(39,122	)	(43,275	)	(6,980	)


Net deferred tax liabilities	(22,385	)	(21,473	)	(3,464	)


Classification on consolidated balance sheets:
Current deferred tax assets	7,664		10,270		1,657
Current deferred tax liabilities	(3,900	)	(9,100	)	(1,468	)
Non-current deferred tax assets	1,789		2,618		422
Non-current deferred tax liabilities	(27,938	)	(25,261	)	(4,075	)

Net deferred tax liabilities	(22,385	)	(21,473	)	(3,464	)

Share-based compensation

12 Months Ended

Mar. 31, 2015

Share-based compensation.

Schedule of share-based compensation expense

	Year ended March 31,
	2013	2014	2015	2015
	RMB	RMB	RMB	US$

Direct costs	—	—	416	67
Sales and marketing	—	—	4,624	746
General and administrative	—	—	11,495	1,854

Total share-based compensation expense	—	—	16,535	2,667

Net income per share (Tables)

12 Months Ended

Mar. 31, 2015

Net income per share

Schedule of Basic and Diluted Net Earnings Per Share

	Year ended March 31,
	Note	2013		2014		2015		2015
		RMB		RMB		RMB		US$
Numerator:
Net income attributable to the Company’s shareholders		112,447		131,903		107,292		17,308
Earnings allocated to participating convertible notes	(i)	(6,053	)	(15,050	)	(8,108	)	(1,308	)


Net income for basic and diluted net income per share		106,394		116,853		99,184		16,000


Denominator:
Weighted average ordinary shares outstanding for basic and diluted net income per share		71,527,698		73,003,248		73,003,248		73,003,248


Net income per share attributable to ordinary shares:
- Basic		1.49		1.60		1.36		0.22

- Diluted	(ii)	1.49		1.60		1.36		0.22

Notes:

(i)

(ii)

Related party transactions (Tables)

12 Months Ended

Mar. 31, 2015

Related party transactions

Schedule of Related Party Transactions

		Year ended March 31,
	Note	2013	2014	2015	2015
		RMB	RMB	RMB	US$

Rental of properties	(i)	1,440	1,440	1,440	232
Raw material purchase	(ii)	—	14,336	15,683	2,530
Consultancy expenses	(iii)	—	904	1,984	320
Interest expenses	14	18,761	37,994	40,008	6,454
License fee	(iv)	—	—	321	52

		March 31,
	Note	2014	2015	2015
		RMB	RMB	US$

Current liabilities:
Amounts due to related parties	(i), (ii) & 14	21,453	20,802	3,355

Note:

(i)

(ii)

(iii)

(iv)

During the year ended March 31, 2015, CGL charged a license fee payable to the Group for an amount of RMB321 (US$52).

Business and credit concentrations (Tables)

12 Months Ended

Mar. 31, 2015

Business and credit concentrations

Schedule of Major Suppliers

	Year ended March 31,
Suppliers	2013		2014		2015
	RMB	%	RMB	%	RMB	US$	%

China Bright Group Co. Limited	—	—	14,336	23	15,683	2,530	25
Hangzhou Baitong Biological Technology Co., Ltd.	7,783	15	—	—	6,600	1,065	10
Shanghai Qiangzhi Biological Technology Co., Ltd.	11,152	22	7,195	11	—	—	—
Cesca Therapeutics Inc.	—	—	10,841	17	—	—	—

Total	18,935	37	32,372	51	22,283	3,595	35

Commitments and contingencies (Tables)

12 Months Ended

Mar. 31, 2015

Commitments and contingencies

Schedule of Future Minimum Lease Payments

	March 31, 2015
	RMB	US$
Fiscal years ending March 31,
2016	1,799	290
2017	1,668	270
2018	1,596	257
2019	1,596	257
2020	1,106	178

Total payments	7,765	1,252

Schedule of Future Minimum Payments Under the Co-Operation Agreements

	March 31, 2015
	RMB	US$
Fiscal years ending March 31,
2016	5,800	936
2017	5,800	936
2018	5,800	936
2019	5,800	936
2020	5,800	936
2021 and thereafter	65,767	10,608

Total payments	94,767	15,288

Principal activities, reorganization and reverse recapitalization, and basis of presentation (Details) In Thousands, except Share data, unless otherwise specified	1 Months Ended		12 Months Ended			1 Months Ended		0 Months Ended			1 Months Ended		1 Months Ended			1 Months Ended
	Nov. 30, 2012 USD ($)	Nov. 30, 2012 CNY	Mar. 31, 2013 CNY	Mar. 31, 2015 item	Mar. 31, 2015 PRC item	Feb. 28, 2011 Zhejiang Province USD ($)	Feb. 28, 2011 Zhejiang Province CNY	Nov. 03, 2008 China Cord Blood Services (CCBS) Share Exchange Agreement	Jun. 30, 2009 China Cord Blood Services (CCBS) Share Exchange Agreement	Nov. 03, 2008 China Cord Blood Services (CCBS) Share Exchange Agreement USD ($)	Aug. 31, 2009 China Cord Blood Services (CCBS) Agreements for remaining shares	Jan. 31, 2008 China Stem Cells Holdings Limited (CSC Holdings) PRC item	Nov. 30, 2012 China Stem Cells (South) Company Limited USD ($)	Nov. 30, 2012 China Stem Cells (South) Company Limited CNY	May 31, 2007 China Stem Cells (South) Company Limited	May 31, 2007 China Stem Cells (South) Company Limited Guangzhou Nuoya CNY	Dec. 31, 2010 Zhejiang Lukou CNY
Principal activities, reorganization and reverse recapitalization, and basis of presentation
Number of cord blood banking licenses issued				7
Number of cord blood banking licenses issued that are held by the Company				3
Subsidiary or Equity Method Investee
Maximum number of shares of Company common stock issuable under agreement										57,851,240
Percentage of acquiree's ordinary shares sold to Company								100.00%
Percentage of acquiree's redeemable ordinary shares sold to Company								76.00%			24.00%
Percentage of equity interests in acquiree sold to Company								93.94%
Consideration										$ 328,790
Shares of Company common stock issued as consideration								54,345,104			3,506,136
Value per share of consideration										$ 6.05
Percentage of equity interest in subsidiary															90.00%		90.00%
Consideration received in stock transaction	20,800
Treasury shares sold to CGL	7,314,015	7,314,015	7,314,015
Treasury shares sold to CGL, as a percent of the Company's ordinary shares	10.00%	10.00%
Percentage of ownership after transaction									91.70%
Number of main subsidiaries					3							2
Payments to acquire interest in subsidiary																30,949
Payment for repurchase of common stock													16,800
Net proceeds from sale of equity	4,000	25,320	25,320
Consideration for operating rights						12,500	82,124
Capital injection from Group																	45,000
Credit to additional paid-in capital on reissuance of treasury stock		3,341
Charge to paid-in capital for shares repurchased														70,774
Ownership interest by noncontrolling owner																	10.00%
Percentage of shares repurchased													10.00%	10.00%
Contribution of property from non-controlling interests																	5,000

Summary of significant accounting policies (Details 2) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2015 USD ($)	Mar. 31, 2015 CNY	Mar. 31, 2014 USD ($)	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY	Mar. 31, 2012 CNY	Mar. 31, 2015 PRC USD ($)	Mar. 31, 2015 PRC CNY	Mar. 31, 2014 PRC CNY	Mar. 31, 2015 U.S. dollar USD ($)	Mar. 31, 2015 U.S. dollar CNY	Mar. 31, 2014 U.S. dollar USD ($)	Mar. 31, 2014 U.S. dollar CNY	Mar. 31, 2015 Australian dollars AUD	Mar. 31, 2015 Australian dollars CNY	Mar. 31, 2014 Australian dollars AUD	Mar. 31, 2014 Australian dollars CNY	Mar. 31, 2015 Renminbi CNY	Mar. 31, 2014 Renminbi CNY	Mar. 31, 2015 Hong Kong dollars CNY	Mar. 31, 2015 Hong Kong dollars HKD	Mar. 31, 2014 Hong Kong dollars CNY	Mar. 31, 2014 Hong Kong dollars HKD	Mar. 31, 2015 Singapore dollars CNY	Mar. 31, 2015 Singapore dollars SGD	Mar. 31, 2014 Singapore dollars CNY	Mar. 31, 2014 Singapore dollars SGD
Cash and Cash Equivalents
Cash and cash equivalents	$ 393,072	2,436,655	$ 303,743	1,882,901	1,494,099	794,311	$ 364,786	2,261,306	1,812,007	$ 28,168	173,419	$ 398	2,474	1	5	242	1,378	2,261,327	1,812,025	1,863	2,361	64,503	81,188	41	9	2,521	515
Accounts Receivable Additional Disclosures [Abstract]
Threshold age of accounts receivable in order to write-off	3 years	3 years

Summary of significant accounting policies (Details 3) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2015 USD ($)	Mar. 31, 2015 CNY	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY	Mar. 31, 2015 Buildings Minimum	Mar. 31, 2015 Buildings Maximum	Mar. 31, 2015 Leasehold improvements	Mar. 31, 2015 Machineries Minimum	Mar. 31, 2015 Machineries Maximum	Mar. 31, 2015 Motor vehicles	Mar. 31, 2015 Furniture, fixtures and office equipment Minimum	Mar. 31, 2015 Furniture, fixtures and office equipment Maximum	Mar. 31, 2015 Construction-in-progress CNY
Property, plant and equipment
Estimated useful lives					37 years 6 months	50 years	10 years	5 years	10 years	5 years	3 years	5 years
Depreciation expense	$ 7,419	45,988	32,444	31,253									0

Summary of significant accounting policies (Details 4) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2015 USD ($) installment payment item	Mar. 31, 2015 CNY	Mar. 31, 2014 CNY installment payment	Mar. 31, 2013 CNY payment installment	Mar. 31, 2015 PRC item
Accounting Policies
Estimated useful life of the operating rights	30 years	30 years
Impairment of long-lived assets		0	0	0
Penalty charged to customers for early termination of the storage service		0
Advertising and promotion costs	$ 4,985	30,899	30,785	19,215
Agreement with customers, blood storage period	18 years	18 years
Agreement with customers, blood storage renewal period	1 year	1 year
Number of customer payment options	3	3	3	3
Number of installments for upfront payment of storage fees for a period of eighteen years, blood storage	4	4	4	4
Customer delinquent period before ceasing of recognizing storage revenue	24 months	24 months	24 months	24 months
Number of main subsidiaries					3
VAT tax rate, currently applicable	6.00%	6.00%
Business tax rate, no longer applicable	5.00%	5.00%
Debt issuance costs, amortization period	5 years	5 years
Number of operating segments	1	1

Accounts receivable, net (Details) In Thousands, unless otherwise specified	Mar. 31, 2015 USD ($)	Mar. 31, 2015 CNY	Mar. 31, 2014 USD ($)	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY	Mar. 31, 2012 CNY	Mar. 31, 2015 Cord blood processing fees USD ($)	Mar. 31, 2015 Cord blood processing fees CNY	Mar. 31, 2014 Cord blood processing fees CNY	Mar. 31, 2015 Cord blood storage fees USD ($)	Mar. 31, 2015 Cord blood storage fees CNY	Mar. 31, 2014 Cord blood storage fees CNY	Mar. 31, 2015 Other USD ($)	Mar. 31, 2015 Other CNY	Mar. 31, 2014 Other CNY
Accounts receivable
Accounts receivable, current portion	$ 19,480	120,762		95,273			$ 12,729	78,911	64,838	$ 6,375	39,522	28,894	$ 376	2,329	1,541
Accounts receivable, noncurrent portion	31,334	194,238		225,496			31,334	194,238	225,496
Accounts receivable	64,338	398,835		383,794
Less: Allowance for doubtful accounts	(13,524)	(83,835)	(10,167)	(63,025)	(50,473)	(52,544)
Total accounts receivable, net	$ 50,814	315,000		320,769

Accounts receivable, net (Details 2) In Thousands, unless otherwise specified	Mar. 31, 2015 USD ($)	Mar. 31, 2015 CNY
Accounts receivable, net
2017	$ 5,082	31,504
2018	4,980	30,874
2019	4,700	29,133
2020	4,768	29,558
2021 and thereafter	29,701	184,118
Non-current gross accounts receivable due for payment	$ 49,231	305,187

Accounts receivable, net (Details 3) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2015 USD ($)	Mar. 31, 2015 CNY	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY
Analysis of the allowance for doubtful accounts
Balance at beginning of year	$ 10,167	63,025	50,473	52,544
Charged to allowance for doubtful accounts	4,040	25,042	17,973	7,468
Write-off charged against the allowance for the year	(683)	(4,232)	(5,421)	(9,539)
Balance at end of year	$ 13,524	83,835	63,025	50,473
Age of accounts receivable written-off	3 years	3 years

Inventories (Details) In Thousands, unless otherwise specified	Mar. 31, 2015 USD ($)	Mar. 31, 2015 CNY	Mar. 31, 2014 CNY	Mar. 31, 2015 Consumables and supplies USD ($)	Mar. 31, 2015 Consumables and supplies CNY	Mar. 31, 2014 Consumables and supplies CNY	Mar. 31, 2015 Processing costs capitalized in donated umbilical cord blood USD ($)	Mar. 31, 2015 Processing costs capitalized in donated umbilical cord blood CNY	Mar. 31, 2014 Processing costs capitalized in donated umbilical cord blood CNY
Inventories
Current portion: - consumables and supplies	$ 3,840	23,803	31,583	$ 3,840	23,803	31,583
Non-current portion: - processing costs capitalized in donated umbilical cord blood	9,392	58,224	48,385				9,392	58,224	48,385
Total current and non-current inventories	$ 13,232	82,027	79,968

Inventories (Details 2) (CNY) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Inventories
Provision for inventories	0	0	0
Weighted average remaining useful life of donated cord blood units	19 years
The estimated increase per annum in number of successful matches of donated units (as a percent)	7.00%

Prepaid expenses and other receivables (Details) In Thousands, unless otherwise specified	Mar. 31, 2015 USD ($)	Mar. 31, 2015 CNY	Mar. 31, 2014 CNY
Prepaid expenses and other receivables
Prepaid expenses	$ 2,311	14,326	20,593
Tax receivables	88	548	13,406
Other receivables	748	4,634	3,011
Total prepaid expenses and other receivables	$ 3,147	19,508	37,010

Property, plant and equipment, net (Details) In Thousands, unless otherwise specified	Mar. 31, 2015 USD ($)	Mar. 31, 2015 CNY	Mar. 31, 2014 CNY	Mar. 31, 2015 Buildings USD ($)	Mar. 31, 2015 Buildings CNY	Mar. 31, 2014 Buildings CNY	Mar. 31, 2015 Leasehold improvements USD ($)	Mar. 31, 2015 Leasehold improvements CNY	Mar. 31, 2014 Leasehold improvements CNY	Mar. 31, 2015 Machineries USD ($)	Mar. 31, 2015 Machineries CNY	Mar. 31, 2014 Machineries CNY	Mar. 31, 2015 Motor vehicles USD ($)	Mar. 31, 2015 Motor vehicles CNY	Mar. 31, 2014 Motor vehicles CNY	Mar. 31, 2015 Furniture, fixtures and equipment USD ($)	Mar. 31, 2015 Furniture, fixtures and equipment CNY	Mar. 31, 2014 Furniture, fixtures and equipment CNY	Mar. 31, 2015 Construction-in-progress USD ($)	Mar. 31, 2015 Construction-in-progress CNY	Mar. 31, 2014 Construction-in-progress CNY
Property, plant and equipment
Property, plant and equipment	$ 128,013	793,551	771,828	$ 93,766	581,252	578,513	$ 2,398	14,864	14,864	$ 22,231	137,811	118,449	$ 2,453	15,209	14,885	$ 6,474	40,132	35,433	$ 691	4,283	9,684
Less: Accumulated depreciation	(30,712)	(190,384)	(145,196)
Total property, plant and equipment, net	$ 97,301	603,167	626,632

Property, plant and equipment, net (Details 3) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2015 USD ($)	Mar. 31, 2015 CNY	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY
Interest cost incurred
Interest cost capitalized			25,912	1,274
Interest cost charged to income	16,309	101,102	70,075	70,097
Total interest cost incurred	$ 16,309	101,102	95,987	71,371

Non-current deposits (Details) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2013 USD ($)	Mar. 31, 2013 CNY	Mar. 31, 2015 USD ($)	Mar. 31, 2015 CNY	Mar. 31, 2014 CNY
Non-current deposits
Investment deposit			$ 33,429	207,226	208,591
Deposit for machineries purchase			5	32	303
Total non-current deposits			33,434	207,258	208,894
Earnest deposit for investment remitted	$ 33,660	207,226

Intangible assets, net (Details) In Thousands, unless otherwise specified	Mar. 31, 2015 USD ($)	Mar. 31, 2015 CNY	Mar. 31, 2014 CNY
Intangible assets, net
Cord blood bank operating rights	$ 22,363	138,628	138,628
Less: Accumulated amortization	(3,662)	(22,700)	(18,079)
Total intangible assets, net	$ 18,701	115,928	120,549

Intangible assets, net (Details 2) In Thousands, unless otherwise specified	12 Months Ended								1 Months Ended			12 Months Ended
	Mar. 31, 2015 USD ($)	Mar. 31, 2015 CNY	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY	Mar. 31, 2015 Guangdong Province USD ($)	Mar. 31, 2015 Guangdong Province CNY	Mar. 31, 2014 Guangdong Province CNY	Mar. 31, 2013 Guangdong Province CNY	Aug. 31, 2011 Zhejiang Province CNY	Feb. 28, 2011 Zhejiang Province USD ($)	Feb. 28, 2011 Zhejiang Province CNY	Mar. 31, 2015 Zhejiang Province USD ($)	Mar. 31, 2015 Zhejiang Province CNY	Mar. 31, 2014 Zhejiang Province CNY	Mar. 31, 2013 Zhejiang Province CNY
Finite-Lived Intangible Assets
Estimated useful life of operating rights	30 years	30 years
Amortization expense of operating rights	$ 745	4,621	4,621	4,621	$ 157	971	971	971				$ 588	3,650	3,650	3,650
Consideration for operating rights										12,500	82,124
Value of acquired operating rights									109,499
Deferred tax liability	$ 4,675	28,982	30,138						27,375
General renewal period with provincial authorities	3 years	3 years
Period of expected cash flow	30 years	30 years

Intangible assets, net (Details 3) In Thousands, unless otherwise specified	Mar. 31, 2015 USD ($)	Mar. 31, 2015 CNY
Intangible assets, net
2016	$ 745	4,621
2017	745	4,621
2018	745	4,621
2019	745	4,621
2020 and thereafter	15,721	97,444
Total amortization expenses	$ 18,701	115,928

Available-for-sale equity securities (Details 2) In Thousands, except Share data, unless otherwise specified	12 Months Ended				1 Months Ended	12 Months Ended							0 Months Ended	1 Months Ended		12 Months Ended
	Mar. 31, 2015 USD ($)	Mar. 31, 2015 CNY	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY	Dec. 31, 2013 Life Corporation Limited - listed on Australian Securities Exchange	Mar. 31, 2011 Life Corporation Limited - listed on Australian Securities Exchange CNY	Mar. 31, 2009 Life Corporation Limited - listed on Australian Securities Exchange CNY	Mar. 31, 2008 Life Corporation Limited - listed on Australian Securities Exchange CNY	Mar. 31, 2015 Life Corporation Limited - listed on Australian Securities Exchange USD ($)	Mar. 31, 2015 Life Corporation Limited - listed on Australian Securities Exchange CNY	Mar. 31, 2014 Life Corporation Limited - listed on Australian Securities Exchange CNY	Jun. 30, 2011 Life Corporation Limited - listed on Australian Securities Exchange	Mar. 31, 2015 Life Corporation Limited - listed on Australian Securities Exchange Maximum	Aug. 31, 2014 Cordlife Group Limited - listed on Singapore Exchange SGD	Feb. 28, 2014 Cordlife Group Limited - listed on Singapore Exchange SGD	Mar. 31, 2015 Cordlife Group Limited - listed on Singapore Exchange USD ($)	Mar. 31, 2015 Cordlife Group Limited - listed on Singapore Exchange CNY	Mar. 31, 2015 Cordlife Group Limited - listed on Singapore Exchange SGD	Mar. 31, 2014 Cordlife Group Limited - listed on Singapore Exchange CNY	Mar. 31, 2013 Cordlife Group Limited - listed on Singapore Exchange CNY	Jun. 30, 2011 Cordlife Group Limited - listed on Singapore Exchange
Schedule of Available-for-sale Securities
Ordinary shares acquired						6,841,666	5,795,000	11,730,000								1,150,000	1,150,000	1,150,000
Cost to acquire ordinary shares	$ 750	4,647				13,245	11,172	53,699								$ 750	4,647
Ordinary shares held						24,366,666			8,122,222	8,122,222	8,122,222	24,366,666				25,516,666	25,516,666	25,516,666	24,366,666		24,366,666
Percentage equity interest owned									11.40%	11.40%	11.40%					9.80%	9.80%	9.80%	9.20%
Stock reverse-split ratio (as a percent)					0.33
Announced dividends per ordinary share														0.01	0.01
Dividend income	378	2,344	9,911	4,685												378	2,344	487	2,414	4,685
Cost basis of the available-for-sale equity securities	7,314	45,337	40,690
Total unrealized net holding gain (loss)									(1,116)	(6,918)	(6,527)					15,448	95,763		121,047
The aggregate fair values of the available-for-sale equity securities	$ 19,748	122,416	144,247
Length of time which the market value of LFC was less than cost													6 months

Other investment (Details) In Thousands, unless otherwise specified	12 Months Ended				1 Months Ended			12 Months Ended
	Mar. 31, 2015 USD ($)	Mar. 31, 2015 CNY	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY	Feb. 28, 2013 Qilu Stem Cells USD ($)	Feb. 28, 2013 Qilu Stem Cells CNY	May 31, 2010 Qilu Stem Cells	Mar. 31, 2015 Qilu Stem Cells CNY	Mar. 31, 2014 Qilu Stem Cells CNY	Mar. 31, 2013 Qilu Stem Cells CNY
Schedule of Equity Method Investments [Line Items]
Percentage equity interest owned					24.00%	24.00%	19.92%
Percentage equity interest acquired					4.08%	4.08%	19.92%
Cash paid for equity interest				54,766	$ 8,650	54,766
Unlisted equity securities, at cost	30,510	189,129	189,129
Dividend income	$ 378	2,344	9,911	4,685				0	7,497	0

Accrued expenses and other payables (Details) In Thousands, unless otherwise specified	Mar. 31, 2015 USD ($)	Mar. 31, 2015 CNY	Mar. 31, 2014 CNY	Mar. 31, 2015 Convertible notes USD ($)	Mar. 31, 2015 Convertible notes CNY	Mar. 31, 2014 Convertible notes CNY
Debt Instrument
Insurance premium received on behalf of an insurance company	$ 3,233	20,035	15,292
Other tax payables	534	3,312	3,927
Accrued salaries, bonus and welfare expenses	3,392	21,026	23,005
Accrued consultancy and professional fees	530	3,287	3,599
Accrued interest on convertible notes				4,197	26,017	26,188
Payable for property, plant and equipment	112	694	15,969
Other payables	2,099	13,010	14,579
Total accrued expenses and other payables	$ 14,097	87,381	102,559
Interest rate				7.00%	7.00%

Deferred revenue (Details) In Thousands, unless otherwise specified	Mar. 31, 2015 USD ($)	Mar. 31, 2015 CNY	Mar. 31, 2014 CNY	Mar. 31, 2015 Payments by customers prior to completion of cord blood processing services USD ($)	Mar. 31, 2015 Payments by customers prior to completion of cord blood processing services CNY	Mar. 31, 2014 Payments by customers prior to completion of cord blood processing services CNY	Mar. 31, 2015 Unearned storage fees USD ($)	Mar. 31, 2015 Unearned storage fees CNY	Mar. 31, 2014 Unearned storage fees CNY
Deferred revenue
Current portion	$ 35,512	220,140	196,432
Non-current portion	177,351	1,099,399	823,921
Total current and non-current deferred revenue	$ 212,863	1,319,539	1,020,353	$ 14,082	87,296	93,597	$ 198,781	1,232,243	926,756

Deferred revenue (Details 2) (Unearned storage fees) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2015 USD ($)	Mar. 31, 2015 CNY	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY
Analysis of unearned storage fees
Balance at beginning of year	$ 149,501	926,756	608,115	361,034
Deferred revenue arising from new customers	82,164	509,334	485,290	376,536
Credited to income	(32,884)	(203,847)	(166,649)	(129,455)
Balance at end of year	$ 198,781	1,232,243	926,756	608,115

Convertible notes (Details) In Thousands, except Per Share data, unless otherwise specified	12 Months Ended				1 Months Ended			12 Months Ended					12 Months Ended
	Mar. 31, 2015	Mar. 31, 2013 CNY	Dec. 01, 2014 GM Notes USD ($)	Nov. 30, 2014 GM Notes USD ($)	Nov. 30, 2014 Golden Meditech Holdings Limited (GMHL) GM Notes USD ($)	Nov. 30, 2014 Magnum GM Notes USD ($)	Nov. 30, 2014 Cordlife Group Limited - listed on Singapore Exchange GM Notes USD ($)	Mar. 31, 2015 Convertible notes	Mar. 31, 2015 Convertible notes KKR Notes	Mar. 31, 2013 Convertible notes KKR Notes USD ($)	Mar. 31, 2013 Convertible notes KKR Notes CNY	Apr. 27, 2012 Convertible notes KKR Notes USD ($)	Mar. 31, 2015 Convertible notes GM Notes Golden Meditech Holdings Limited (GMHL)	Mar. 31, 2013 Convertible notes GM Notes Golden Meditech Holdings Limited (GMHL) USD ($)	Mar. 31, 2013 Convertible notes GM Notes Golden Meditech Holdings Limited (GMHL) CNY	Oct. 03, 2012 Convertible notes GM Notes Golden Meditech Holdings Limited (GMHL) USD ($)
Debt Instrument
Aggregate principal amount						$ 25,000	$ 25,000					$ 65,000				$ 50,000
Interest rate								7.00%				7.00%				7.00%
Conversion price per share												$ 2.838				$ 2.838
Proceeds from issuance of convertible notes		730,493								65,000				50,000
Issuance costs incurred											14,260				4,258
Guaranteed internal rate of return									12.00%				12.00%
Default interest rate								22.50%
Threshold amount of new debt which must be approved												22,000
Debt issuance costs, amortization period	5 years							5 years
Proceeds from sale of convertible notes					88,090
Denomination of the fair value of the convertible notes			$ 25,000	$ 50,000

Convertible notes (Details 2) (Convertible notes) In Thousands, unless otherwise specified	Mar. 31, 2015 USD ($)	Mar. 31, 2015 CNY	Mar. 31, 2014 CNY	Mar. 31, 2015 KKR Notes USD ($)	Mar. 31, 2015 KKR Notes CNY	Mar. 31, 2014 KKR Notes CNY	Mar. 31, 2015 GM Notes USD ($)	Mar. 31, 2015 GM Notes CNY	Mar. 31, 2014 GM Notes CNY
Debt Instrument
Principal amount of Notes				$ 64,554	400,175	403,315
Principal amount of Notes							49,658	307,828	310,302
Cumulative interest payable	17,398	107,848	64,136
Carrying amount	$ 131,610	815,851	777,753

Convertible notes (Details 3) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2015 USD ($)	Mar. 31, 2015 CNY	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY	Mar. 31, 2015 Convertible notes USD ($)	Mar. 31, 2015 Convertible notes CNY	Mar. 31, 2014 Convertible notes CNY	Mar. 31, 2013 Convertible notes CNY	Mar. 31, 2015 Convertible notes KKR Notes USD ($)	Mar. 31, 2015 Convertible notes KKR Notes CNY	Mar. 31, 2014 Convertible notes KKR Notes CNY	Mar. 31, 2013 Convertible notes KKR Notes CNY	Mar. 31, 2015 Convertible notes GM Notes USD ($)	Mar. 31, 2015 Convertible notes GM Notes CNY	Mar. 31, 2014 Convertible notes GM Notes CNY	Mar. 31, 2013 Convertible notes GM Notes CNY
Debt Instrument
Notes interest incurred									$ 8,586	53,222	50,475	45,959
Notes interest incurred	6,454	40,008	37,994	18,761									6,454	40,008	37,994	18,761
Amortization of debt issuance costs	582	3,610	3,610	3,062	582	3,610	3,610	3,062
Notes related interest cost capitalized							(24,822)	(1,207)
Total interest expense					$ 15,622	96,840	67,257	66,575

Shareholders' equity (Details) In Thousands, except Share data, unless otherwise specified	0 Months Ended				1 Months Ended	12 Months Ended									0 Months Ended
	Jul. 30, 2014	Jul. 24, 2013	Aug. 03, 2011	Sep. 15, 2010	Nov. 30, 2012	Mar. 31, 2015 USD ($)	Mar. 31, 2015 CNY	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY	Jul. 30, 2014 USD ($)	Jul. 24, 2013 USD ($)	Jul. 31, 2012 USD ($)	Mar. 31, 2012	Sep. 15, 2010 USD ($)	Jul. 30, 2015 Subsequent event	Jul. 30, 2015 Subsequent event USD ($)
Statement
Ordinary shares, shares outstanding						73,003,248	73,003,248	73,003,248	73,003,248				73,140,147
Purchase of Treasury Stock, shares									7,450,914
Purchase of Treasury Stock									131,302
Sale of treasury shares, shares					7,314,015				7,314,015
Treasury stock, shares						136,899	136,899	136,899	136,899
Share repurchase program, amount										20,000	20,000	20,000		15,000		20,000
Share repurchase program, period	12 months	12 months													12 months
Share repurchase program, original period				1 year
Share repurchase program, refreshment period			12 months
Beijing Jiachenhong, Guangzhou Nuoya and Zhejiang Lukou required to transfer net income, percentage						10.00%	10.00%
The percentage of their respective registered capital that the statutory surplus reserve must reach before Beijing Jiachenhong, Guangzhou Nuoya and Zhejiang Lukou are not required to transfer their net income						50.00%	50.00%
The percent of registered capital that must be retained in the reserve balance after conversion into issued capital						25.00%	25.00%
Transfers made to the statutory surplus reserve by Beijing Jiachenhong and Guangzhou Nuoya						1,367	8,471	22,858	22,638
Accumulated statutory surplus reserve						$ 17,649	109,408	100,937

Income tax (Details) In Thousands, unless otherwise specified	12 Months Ended									87 Months Ended	12 Months Ended		51 Months Ended	21 Months Ended	63 Months Ended	9 Months Ended
	Mar. 31, 2015 USD ($)	Mar. 31, 2015 CNY	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY	Mar. 31, 2015 Hong Kong Profits Tax CNY	Mar. 31, 2014 Hong Kong Profits Tax CNY	Mar. 31, 2013 Hong Kong Profits Tax CNY	Mar. 31, 2015 PRC tax laws and rules USD ($)	Mar. 31, 2015 PRC tax laws and rules CNY	Mar. 31, 2015 PRC tax laws and rules	Mar. 31, 2015 PRC subsidiary	Mar. 31, 2014 PRC subsidiary CNY	Mar. 31, 2015 Beijing Jiachenhong	Dec. 31, 2016 Beijing Jiachenhong Scenario forecast	Mar. 31, 2015 Guangzhou Nuoya	Dec. 31, 2015 Guangzhou Nuoya Scenario forecast
Income Tax
Tax expense	$ 7,635	47,327	58,398	38,543	0	0	0
Statutory income tax rate											25.00%
HNTE preferential tax rate													15.00%	15.00%	15.00%	15.00%
Withholding tax rate										10.00%
Withholding tax amount on dividends												6,000
Provision for withholding tax	1,468	9,100	3,900
Provision for income taxes on undistributed earnings		0
Unremitted earnings that may be subject to the withholding tax	153,752	953,111
Unrecognized deferred tax liability from unremitted earnings of PRC subsidiaries	15,375	95,311
Interest and penalties related to unrecognized tax benefits		0	0	0
Statute of limitation, underpayment due to computational errors								3 years	3 years
Statute of limitation, special circumstances where underpayment is more than RMB100								5 years	5 years
Statute of limitation, transfer pricing issues								10 years	10 years
Underpayment of taxes threshold that extends the statute of limitation								$ 16	100

Income tax (Details 2) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2015 USD ($)	Mar. 31, 2015 CNY	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY
Income tax
The PRC	$ 45,860	284,288	316,933	260,462
Non-PRC	(20,836)	(129,168)	(126,009)	(102,277)
Income before income tax expense	$ 25,024	155,120	190,924	158,185

Income tax (Details 3) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2015 USD ($)	Mar. 31, 2015 CNY	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY
Income tax
Current tax expense	$ 7,782	48,239	50,000	38,737
Deferred tax benefit	(147)	(912)	8,398	(194)
Total income tax expense	$ 7,635	47,327	58,398	38,543

Income tax (Details 4) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2015 USD ($)	Mar. 31, 2015 CNY	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY
Income tax
Income before income tax expense	$ 25,024	155,120	190,924	158,185
Computed "expected" tax expense	6,256	38,780	47,731	39,546
Non-PRC entities not subject to income tax	5,209	32,292	31,502	25,569
PRC dividend withholding tax	839	5,200	9,887
Non-taxable income			(1,874)
Tax rate differential, preferential rate	(4,785)	(29,663)	(29,011)	(26,015)
Others	116	718	163	(557)
Total income tax expense	$ 7,635	47,327	58,398	38,543

Income tax (Details 5) In Thousands, unless otherwise specified	Mar. 31, 2015 USD ($)	Mar. 31, 2015 CNY	Mar. 31, 2014 CNY
Deferred tax assets:
Accounts receivable	$ 1,609	9,975	6,812
Non-current accounts receivable	1,431	8,871	6,406
Inventories	367	2,278	2,293
Others	109	678	1,226
Net deferred tax assets	3,516	21,802	16,737
Deferred tax liabilities:
Deferred revenue	(14)	(86)	(96)
Property, plant and equipment	(823)	(5,107)	(4,988)
PRC dividend withholding tax	(1,468)	(9,100)	(3,900)
Intangible assets	(4,675)	(28,982)	(30,138)
Deferred tax liabilities	(6,980)	(43,275)	(39,122)
Net deferred tax liabilities	(3,464)	(21,473)	(22,385)
Classification on consolidated balance sheets
Current deferred tax assets	1,657	10,270	7,664
Current deferred tax liabilities	(1,468)	(9,100)	(3,900)
Non-current deferred tax assets	422	2,618	1,789
Non-current deferred tax liabilities	(4,075)	(25,261)	(27,938)
Net deferred tax liabilities	$ (3,464)	(21,473)	(22,385)

Share-based compensation (Details) (Restricted Share Unit) In Thousands, except Share data, unless otherwise specified	0 Months Ended	12 Months Ended		50 Months Ended		12 Months Ended
	Dec. 15, 2014	Mar. 31, 2015 USD ($)	Mar. 31, 2015 CNY	Mar. 31, 2015	Dec. 15, 2014 USD ($)	Mar. 31, 2015 Direct costs USD ($)	Mar. 31, 2015 Direct costs CNY	Mar. 31, 2015 Sales and marketing USD ($)	Mar. 31, 2015 Sales and marketing CNY	Mar. 31, 2015 General and administrative USD ($)	Mar. 31, 2015 General and administrative CNY
Share-based compensation
Term of RSU Scheme				10 years
Number of equivalent shares	1
Shares granted in period	7,300,000
Ordinary shares issued and deposited into the Trust (in shares)	7,080,000
Fair value of each RSU					$ 4.15
Outstanding RSUs (in shares)		7,300,000	7,300,000	7,300,000
Exercisable RSUs (in shares)		0	0	0
Weighted average remaining contract life		3 years	3 years
Total share-based compensation expense		$ 2,667	16,535			$ 67	416	$ 746	4,624	$ 1,854	11,495

Net income per share (Details) In Thousands, except Share data, unless otherwise specified	12 Months Ended
	Mar. 31, 2015 USD ($)	Mar. 31, 2015 CNY	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY	Mar. 31, 2015 Convertible notes USD ($)	Mar. 31, 2015 Convertible notes CNY	Mar. 31, 2014 Convertible notes CNY	Mar. 31, 2013 Convertible notes CNY
Net income per share
Interest rate					7.00%	7.00%
Numerator:
Net income attributable to the Company's shareholders	$ 17,308	107,292	131,903	112,447
Earnings allocated to participating convertible notes					(1,308)	(8,108)	(15,050)	(6,053)
Net income for basic and diluted net income per share	$ 16,000	99,184	116,853	106,394
Denominator:
Weighted average ordinary shares outstanding for basic and diluted net income per share	73,003,248	73,003,248	73,003,248	71,527,698
Net income per share attributable to ordinary shares:
Basic	$ 0.22	1.36	1.60	1.49
Diluted	$ 0.22	1.36	1.60	1.49
Anti-dilutive ordinary shares					40,521,495	40,521,495	40,521,495	40,521,495

Related party transactions (Details) In Thousands, unless otherwise specified	12 Months Ended				1 Months Ended	12 Months Ended				66 Months Ended		12 Months Ended								60 Months Ended
	Mar. 31, 2015 USD ($)	Mar. 31, 2015 CNY	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY	Jun. 30, 2009 Beijing Jingjing Rental of properties CNY	Mar. 31, 2015 Beijing Jingjing Rental of properties USD ($)	Mar. 31, 2015 Beijing Jingjing Rental of properties CNY	Mar. 31, 2014 Beijing Jingjing Rental of properties CNY	Mar. 31, 2013 Beijing Jingjing Rental of properties CNY	Dec. 31, 2014 Beijing Jingjing Rental of properties CNY	Mar. 31, 2014 GMHL, Beijing Jingjing and China Bright CNY	Mar. 31, 2015 China Bright Group Co. Limited Raw material purchase USD ($)	Mar. 31, 2015 China Bright Group Co. Limited Raw material purchase CNY	Mar. 31, 2014 China Bright Group Co. Limited Raw material purchase CNY	Mar. 31, 2015 Golden Meditech (S) Pte Ltd. Consultancy expenses USD ($)	Mar. 31, 2015 Golden Meditech (S) Pte Ltd. Consultancy expenses CNY	Mar. 31, 2014 Golden Meditech (S) Pte Ltd. Consultancy expenses CNY	Mar. 31, 2015 Cordlife Group Limited - listed on Singapore Exchange License fee USD ($)	Mar. 31, 2015 Cordlife Group Limited - listed on Singapore Exchange License fee CNY	Dec. 31, 2019 Scenario forecast Beijing Jingjing Rental of properties USD ($)	Dec. 31, 2019 Scenario forecast Beijing Jingjing Rental of properties CNY	Mar. 31, 2015 Magnum Cordlife Group Limited - listed on Singapore Exchange GMHL, Beijing Jingjing and China Bright USD ($)	Mar. 31, 2015 Magnum Cordlife Group Limited - listed on Singapore Exchange GMHL, Beijing Jingjing and China Bright CNY
Related Party Transaction
Expenses incurred						$ 232	1,440	1,440	1,440						$ 320	1,984	904	$ 52	321
Raw material purchase												2,530	15,683	14,336
Interest expenses	6,454	40,008	37,994	18,761
Amounts due to related parties	3,355	20,802	21,453								21,453											3,355	20,802
Monthly rental payment					174					120										$ 19	120
Period of lease										5 years 6 months										5 years	5 years

Business and credit concentrations (Details) (Supplier, Purchases of raw materials) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2015 USD ($)	Mar. 31, 2015 CNY	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY	Mar. 31, 2015 China Bright Group Co. Limited USD ($)	Mar. 31, 2015 China Bright Group Co. Limited CNY	Mar. 31, 2014 China Bright Group Co. Limited CNY	Mar. 31, 2015 Hangzhou Baitong Biological Technology Co., Ltd. USD ($)	Mar. 31, 2015 Hangzhou Baitong Biological Technology Co., Ltd. CNY	Mar. 31, 2013 Hangzhou Baitong Biological Technology Co., Ltd. CNY	Mar. 31, 2014 Shanghai Qiangzhi Biological Technology Co., Ltd. CNY	Mar. 31, 2013 Shanghai Qiangzhi Biological Technology Co., Ltd. CNY	Mar. 31, 2014 Cesca Therapeutics Inc. CNY
Concentration Risk
Percentage of purchases	35.00%	35.00%	51.00%	37.00%	25.00%	25.00%	23.00%	10.00%	10.00%	15.00%	11.00%	22.00%	17.00%
Purchases from suppliers	$ 3,595	22,283	32,372	18,935	$ 2,530	15,683	14,336	$ 1,065	6,600	7,783	7,195	11,152	10,841

Commitments and contingencies (Details 2) In Thousands, unless otherwise specified	Mar. 31, 2015 USD ($)	Mar. 31, 2015 CNY
Commitments and contingencies
2016	$ 290	1,799
2017	270	1,668
2018	257	1,596
2019	257	1,596
2020	178	1,106
Total payments	$ 1,252	7,765

Commitments and contingencies (Details 3) In Thousands, unless otherwise specified							1 Months Ended		88 Months Ended	1 Months Ended		47 Months Ended
	Mar. 31, 2015 Research and development of medicines USD ($)	Mar. 31, 2015 Research and development of medicines CNY	Mar. 31, 2014 Research and development of medicines USD ($)	Mar. 31, 2014 Research and development of medicines CNY	Mar. 31, 2015 Co-operation agreement USD ($)	Mar. 31, 2015 Co-operation agreement CNY	Oct. 31, 2013 Co-operation agreement Peking University People's Hospital USD ($)	Oct. 31, 2013 Co-operation agreement Peking University People's Hospital CNY	Sep. 30, 2013 Co-operation agreement Peking University People's Hospital CNY	Oct. 31, 2013 Co-operation agreement Guangdong Women and Children's Hospital and Health Institute USD ($)	Oct. 31, 2013 Co-operation agreement Guangdong Women and Children's Hospital and Health Institute CNY	Sep. 30, 2013 Co-operation agreement Guangdong Women and Children's Hospital and Health Institute CNY
Contractual commitments
Commitment as of year end	$ 323	2,000	$ 323	2,000	$ 15,288	94,767
Annual advisory fee							$ 419	2,600	2,000	$ 516	3,200	2,000
Annual advisory fee, time period							20 years	20 years

Commitments and contingencies (Details 4) (Co-operation agreement) In Thousands, unless otherwise specified	Mar. 31, 2015 USD ($)	Mar. 31, 2015 CNY
Future minimum payments under cooperation agreements
2016	$ 936	5,800
2017	936	5,800
2018	936	5,800
2019	936	5,800
2020	936	5,800
2021 and thereafter	10,608	65,767
Total payments	$ 15,288	94,767

Bank loan	12 Months Ended
Bank loan	Mar. 31, 2015
Bank loan
Bank loan	11Bank loan On August 12, 2013, the Group borrowed RMB60,000 from Hangzhou Bank for one year. The loan bears a monthly fixed interest rate at 0.6%. The Group repaid the bank loan in full on August 11, 2014. On August 25, 2014, the Group borrowed RMB60,000 (US$9,679) from Hangzhou Bank for one year. The loan bears a monthly fixed interest rate at 0.6%.

Bank loan (Details) (Short-term bank loan) In Thousands, unless otherwise specified	0 Months Ended
	Aug. 25, 2014 USD ($)	Aug. 25, 2014 CNY	Aug. 12, 2013 CNY
Bank loan
Amount borrowed	$ 9,679	60,000	60,000
Term of the loan	1 year	1 year	1 year
Monthly fixed interest rate (as a percent)	0.60%	0.60%	0.60%

Summary of significant accounting policies (Details)	Mar. 31, 2015
Summary of significant accounting policies
Foreign currency convenience translation rate	6.1990

Property, plant and equipment, net (Details 4) In Thousands, unless otherwise specified	Mar. 31, 2015 USD ($)	Mar. 31, 2015 CNY	Mar. 31, 2014 CNY	Mar. 31, 2015 Buildings Short-term bank loan USD ($)	Mar. 31, 2015 Buildings Short-term bank loan CNY	Mar. 31, 2014 Buildings Short-term bank loan CNY
Property, plant and equipment
Carrying value of buildings collateralized for loans				$ 17,343	107,509	114,570
Bank loan	$ 9,679	60,000	60,000	$ 9,679	60,000	60,000

Revenues (Details) In Thousands, unless otherwise specified	12 Months Ended
Revenues (Details) In Thousands, unless otherwise specified	Mar. 31, 2015 USD ($)	Mar. 31, 2015 CNY	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY	Mar. 31, 2015 Cord blood processing fees USD ($)	Mar. 31, 2015 Cord blood processing fees CNY	Mar. 31, 2014 Cord blood processing fees CNY	Mar. 31, 2013 Cord blood processing fees CNY	Mar. 31, 2015 Cord blood storage fees USD ($)	Mar. 31, 2015 Cord blood storage fees CNY	Mar. 31, 2014 Cord blood storage fees CNY	Mar. 31, 2013 Cord blood storage fees CNY	Mar. 31, 2015 Other USD ($)	Mar. 31, 2015 Other CNY	Mar. 31, 2014 Other CNY	Mar. 31, 2013 Other CNY
Revenues from External Customers
Revenues	$ 102,456	635,122	572,857	526,123	$ 69,086	428,261	403,058	394,641	$ 32,884	203,847	166,649	129,455	$ 486	3,014	3,150	2,027

Fair value measurements (Details) In Thousands, unless otherwise specified	Mar. 31, 2015 Level 3 USD ($)	Mar. 31, 2015 Level 3 CNY	Mar. 31, 2014 Level 3 USD ($)	Mar. 31, 2015 Carrying value USD ($)	Mar. 31, 2015 Carrying value CNY	Mar. 31, 2014 Carrying value CNY
Fair value measurements
Fair value of convertible notes	$ 218,666	1,355,511	$ 176,640
Carrying value of convertible notes				$ 131,610	815,851	777,753

Subsequent events (Details) (USD $)	Mar. 31, 2015 Convertible notes	Apr. 27, 2015 Golden Meditech Holdings Limited (GMHL) Convertible notes Subsequent event	Apr. 27, 2015 Golden Meditech Holdings Limited (GMHL) Scenario forecast Subsequent event
Subsequent events
Sale price per share in cash			$ 6.40
Interest rate	7.00%	7.00%